(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 February 2001 (22.02.2001)

PCT

(10) International Publication Number
WO 01/12803 A2

(51) International Patent Classification[7]: C12N 15/11

(21) International Application Number: PCT/US00/22086

(22) International Filing Date: 11 August 2000 (11.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/149,313 17 August 1999 (17.08.1999) US

(71) Applicant *(for all designated States except US)*: **BETH ISRAEL DEACONESS MEDICAL CENTER, INC.** [US/US]; 1 Deaconess Road, Boston, MA 02215 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **INOUYE, Roger, T.** [US/US]; 23 Roberts Road, Wellesley, MA 02481 (US). **TORRES-VIERA, Carlos** [VE/VE]; Calle Andrea de Ledesma, Qta La Torrera, Urb Sorocaima, Caracas, Venezuela (VE). **MOELLERING, Robert** [US/US]; 49 Longfellow Road, Wellesley Hills, MA 02481-5220 (US). **GOLD, Howard** [US/US]; Apartment 610, 135 Pleasant Street, Brookline, MA 02446-3489 (US). **ELIOPOULOS, George, M.** [US/US]; 5 Laurel Circle, Needham, MA 02494 (US).

(74) Agent: **PLUMER, Elizabeth, R.**; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(81) Designated States *(national)*: CA, JP, US.

(84) Designated States *(regional)*: European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

**Published:**
— *Without international search report and to be republished upon receipt of that report.*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviation " appearing at the beginning of each regular issue of the PCT Gazette.*

WO 01/12803 A2

(54) Title: METHODS AND COMPOSITIONS FOR RESTORING ANTIBIOTIC SUSCEPTIBILITY IN GLYCOPEPTIDE-RESISTANT *ENTEROCOCCUS*




(57) Abstract: Methods and compositions for reducing vancomycin resistance in a vancomycin resistant organism is provided. The methods involve delivering to the organism an isolated nucleic acid molecule that hybridizes to a target vancomycin gene and/or that serves as a *VanR*-responsive promoter decoy.

# METHODS AND COMPOSITIONS FOR RESTORING ANTIBIOTIC SUSCEPTIBILITY IN GLYCOPEPTIDE-RESISTANT *ENTEROCOCCUS*

## Related Applications

This application claims priority under 35 USC §119(e) from U.S. Provisional Patent Application Serial No. 60/149,313, filed on August 17, 1999, entitled METHODS AND COMPOSITIONS FOR RESTORING ANTIBIOTIC SUSCEPTIBILITY IN GLYCOPEPTIDE-RESISTANT *ENTEROCOCCUS*. The contents of the provisional application are hereby expressly incorporated by reference.

## Government Support

This work was funded in part by the National Institutes for Allergy and Infectious Diseases/National Institutes of Health under Grant KO8 AI01518. The government may retain certain rights in this invention.

## Field of the Invention

This invention relates to methods for reducing antibiotic resistance in vancomycin resistant bacteria.

## Background of the Invention

Over the past decade, the emergence of antibiotic-resistant bacteria, particularly multidrug-resistant strains, have created an increasingly concerning clinical dilemma (Gold, et al., *N. Engl. J. Med.*, 1996, 335:1445-1453). Included among these pathogens are enterococci which have developed relative, and in some cases, absolute resistance to the mainstays of antimicrobial therapy, including beta-lactam and aminoglycoside antibiotics, and more recently, the glycopeptide, vancomycin (Eliopoulos, G.M., *Infect. Dis. Clin. North. Am.* 1997;11:851-65). While new pharmacologic agents continue to be developed in order to remedy this therapeutic shortfall, drug resistance and consequential treatment failure to even investigational agents such as the streptogramins in the setting of vancomycin-resistant enterococcal infections highlight the ongoing need for effective, potentially novel means of treating these organisms (Chang, et al., *Diag. Microbiol. Infect. Dis.*, 1999;33:299-303).

*Vancomycin Resistant Enterococcus*

Enterococci are Gram-positive cocci which, prior to DNA homology studies, were classified as Lancefield group D streptococci (Moellering, R.C. Jr., In:Mandell GL, Bennett JE and Dolin R eds. *Principles and Practices of Infectious Diseases*. New York:Churchhill Livingstone. 1995:1826-1835). While these organisms are known constituents of the gastrointestinal and genital tract bacterial flora, enterococci have rapidly emerged as clinically relevant pathogens especially in the nosocomial setting. In fact, enterococci are the second most common cause of nosocomial infections in the United States as well as a frequent cause of nosocomial bacteremia (Eliopoulos, G.M., *Infect. Dis. Clin. North. Am.* 1997;11:851-65); Schaberg, et al., *Am. J. Med.*, 1991:91(3B):72S-85S). Far from being inconsequential, the mortality attributable to vancomycin resistant enterococcal bacteremia has been estimated to approach 25% in some studies (Edmond, et al., *Clin. Infect. Dis.*, 1996;23:1234-1239).

*Vancomycin Mechanism-of-Action*

First introduced in the 1950's as a means for treating penicillin-resistant staphylococcal infections, vancomycin, a glycopolypeptide antibiotic, has become the drug-of-choice for the treatment of beta-lactam antibiotic-resistant Gram-positive bacterial infections (Fekety, et al., In: Mandell, et al. *Principles and Practices of Infectious Diseases*. New York:Churchhill Livingstone, 1995;346-354). While other ancillary mechanisms-of-action continue to be investigated, the major mechanism of vancomycin is the inhibition of polymerization and transpeptidation of the bacterial cell wall peptidoglycan (Ge, et al., *Science* 1999;284:507-11). This structure serves an important function in bacteria: the inhibition of osmolysis. In the wildtype enterococci, cell wall production is characterized by peptidoglycan synthesis in which two D-alanines are ligated to form a dipeptide which is then added to the carboxy-terminus of peptidoglycan precursors (Walsh, C.T., *J. Biol. Chem.*, 1989;264:2393-2396). Vancomycin interferes with this process by complexing with the terminal D-alanine residues at the outer portion of the cytoplasmic membrane (Beauregard, et al., *Antimicrob. Agents chemother.*, 1995;39:791-785; Reynolds, et al., *Euro. J. Clin. Microbiol. Intect. Dis.*, 1989;943-950). This blocks subsequent cell wall formation by perturbing the further processing of peptidoglycan precursors by transglycosidases. Vancomycin also blocks catalysis by enterococcal transpeptidases and D,D-carboxypeptidases.

*Vancomycin Resistance*

Several phenotypes of glycopeptide resistance in enterococci have been described (Eliopoulos, G.M., *Infect. Dis. Clin. North. Am.* 1997;11:851-65). Class A glycopeptide resistance (VanA), which was targeted in this study, is found in both the clinically relevant *Enterococcus faecalis* and *Enterococcus faecium* species, and is characterized by high-level vancomycin resistance with MICs ≥ 64 μg/mL as well as resistance to teicoplanin, a related glycopeptide antibiotic (Eliopoulos, G.M., *Infect. Dis. Clin. North. Am.* 1997;11:851-65).

The genotypic characterization of Class A vancomycin resistance has uncovered potential targets for gene-based anti-drug resistance determinant strategy. The genetic basis for VanA phenotypic resistance is a transposon-based operon consisting of 7 genes including *vanR, vanS, vanH, vanA, vanX, vanY, and vanZ* (Arthur, et al., *Antimicrob. agent Chemother.*, 1993;37:1563-1571; Bugg, et al., *Biochem.*, 1991;30:2017-2021) (Figure 1). The products of these genes function in concert to negate the inhibitory effects of vancomycin by, in essence, allowing for an alternate biosynthetic pathway for the production of cell wall precursors which less avidly bind vancomycin. The transcription of *vanH, -A, and –X* are under the control of the *vanH* promoter. This promoter is inducible by the binding of the phosphorylated gene product of *vanR* (Arthur, et al., *J. Bacteriol.*, 1992;174:2582-2591; Holman, et al., *Biochem.*, 1994;33:4625-4631).

*Therapeutic Gene Transfer Background*

In an attempt to inhibit pathogens which are refractory to conventional pharmacological antimicrobial agents, gene-based therapeutics have been studied, though for the most part, in eukaryotic systems. For example, nucleic acid binding decoys, antisense nucleic acids (antisense RNA and DNA), ribozymes, and trans-dominant mutants are among the many gene therapy motifs which have been used to target the expression of key viral functions in human immunodeficiency virus, type 1; human papilloma virus; hepatitis viruses, and Herpesviridae infections (Chatterjee, et al., *Science*, 1992, 258:1485-1488; Weiss, et al., *Cell. Mol. Life. Sci.*, 1999, 55:334-58; Yamada, et al., *Virol.*, 1996, 70:1596-1601; Inouye, et al., *J. Virol.*, 1997, 71(5):4071-4080; Yamamoto, et al., *Hepatology*, 1999, 30:300-307; Shillitoe, et al., *Cancer Gene Ther.*, 1994, 1:193-204; Flores-Aguilar, et al., *J. Infect. Dis.*, 1997, 175:1308-1316) . Additionally, they have been studied for their ability to inhibit pro-oncogenic cellular functions (Mercola, et al., *Cancer Gene Ther.*, 1995, 2:47-59; Seth, et al., *Cancer Gene Ther.*, 1997, 4:383-390; Rubin, et al., *Curr. Opin. Pediatr.*, 1999, 11:39-46).

A cornerstone of a successful gene-based tactic is that the target nucleic acid sequence encode for pivotal, highly conserved pathogenic functions. In eukaryotic viral and oncologic

systems, antisense nucleic acids, for example, have also been specifically used to inhibit the expression of key viral or cellular functional proteins including the expression of drug resistance determinants (Gao, et al., *Anticancer Res.*, 1998, 18:3073-3076; Inouye, et al., *Antiviral Therapy*, 1999, 4 (Supplement 1):121). In comparison, examples of gene-based strategies in prokaryotic systems are scant (Takada-Guerrier, et al., *Proc. Natl. Acad. Sci* USA, 1997;94:8468-8472; White, et al., *Antimicrob. Agent Chem.*, 1997, 41:2699-2704; Rom, et al., *Am. J. Res. Crit. Care. Med.*, 1997, 156:1993-1998; Nielson, et al., *Nat. Biotech.*, 1998, 16:355-358), and in particular, with enterococci or more specifically, with vancomycin-resistant enterococci, have yet to be reported. Although data have been published on the use of anti-resistance determinant genetic elements in other microorganisms (e.g. *Escherichia coli* and *Staphylococcus aureas*) there are yet no published data on the use of this technology for vancomycin-resistant *Enterococcus* (Takada-Guerrier, et al., *Proc. Natl. Acad. Sci USA*, 1997, 94:8468-8472; White, et al., *Antimicrob. Agent Chem.*, 1997, 41:2699-2704).

## Summary of the Invention

In the most basic of terms, a successful strategy against antibiotic resistant enterococci would require either (1) the retention of antimicrobial activity despite the presence of the drug resistance mechanism (i.e. a lack of cross-resistance), or (2) the perturbation of the antibiotic resistance mechanism itself and, as a consequence, reversion of the bacterium to a drug-susceptible phenotype. In our studies, the unique approach taken towards the treatment of vancomycin-resistant enterococci is of the latter type. Herein, we present a gene-based strategy which targets a key vancomycin resistance determinant and results in the restoration of vancomycin susceptibility in previously glycopeptide-resistant enterococci.

Thus, the invention overcomes the above-noted and other problems of the prior art by providing methods and related compositions for reducing antibiotic resistance in vancomycin resistant microorganisms. More particularly, the present invention provides a gene cassette comprised of the *vanH* promoter and a single copy of a *vanA* antisense gene in an enterococcal shuttle vector. Using this invention, we have demonstrated an ability to increase the vancomycin susceptibility in previously resistant *Enterococcus faecalis*.

According to one aspect of the invention, a method for reducing vancomycin resistance in a vancomycin-resistant organism is provided. The method involves introducing into the organism at least one "anti-sense vancomycin resistance molecule" under conditions to inhibit expression of a vancomycin resistance gene. By "inhibit expression" it is meant to

inhibit replication, transcription, and/or translation of a vancomycin gene since inhibition of any of these processes results in the inhibition of expression of a protein encoded by a vancomycin gene. Exemplary vancomycin-resistant organisms include the Gram-positive bacteria *Enterococcus faecium* and *Enterococcus faecalis* and other bacteria to which these organisms have the potential of transferring resistance determinants, given that VanA is a transferable form of resistance and that it could be transferred to other clinically significant pathogens such as *Streptococcus Pneumocóccus*, and *Staphylococcus*. (See, e.g., Brisson-Noel A., et al., *J. Bacteriol,* 1988, 170:1739-1745).

Preferably, the vancomycin resistant organism is a Gram-positive bacteria and, more preferably, the organism is an *Enterococcus*.

Vancomycin resistance can take a variety of forms depending upon the nature of the gene cluster which mediates the resistance phenotype. Thus, exemplary vancomycin resistant organisms of the invention may exhibit one or more of the following phenotypes: VanA resistance, VanB resistance, VanC resistance, and VanD resistance. VanA resistance is mediated by a gene cluster which includes seven genes: *vanR* (SEQ ID NO:18), *vanS* (SEQ ID NO:19), *vanH* (SEQ ID NO:20), *vanA* (SEQ ID NO:21), *vanX* (SEQ ID NO:22), *vanY* (SEQ ID NO:23), and *vanZ* (SEQ ID NO:24).

In a preferred embodiment in which the vancomycin resistant organism carries a VanA genotype, the antisense vancomycin resistance molecule is selected from the group consisting of antisense molecules which hybridize under stringent conditions to these target genes or to conserved regions of these target genes (e.g., SEQ ID NOS: 5, 6, 7, 8, 9, and 10). As used herein, such antisense molecules to these target genes are referred to as *vanR* antisense molecules, *vanS* anti-sense molecules, *vanH* anti-sense molecules, *vanA* anti-sense molecules, *vanX* anti-sense molecules, *vanY* anti-sense molecules, and *vanZ* anti-sense molecules, respectively. In a particularly preferred embodiment, the organism is a VanA type, and the anti-sense vancomycin resistance molecule hybridizes under stringent conditions to the *vanA* target gene (SEQ ID NO:21), or to a conserved region of the *vanA* gene (e.g., SEQ ID NOs: 7, and 8). In a further preferred embodiment, the organism is a VanA type, and the anti-sense vancomycin resistance molecule hybridizes under stringent conditions to the *vanX* target gene (SEQ ID NO:22), or to a conserved region of the *vanX* gene (e.g., SEQ ID NO:10).

Additionally or alternatively, the vancomycin resistant organism can be a VanB, VanC, and/or VanD type organism and the anti-sense vancomycin resistance molecule is a

nucleic acid molecule which hybridizes under stringent conditions to these target genes (SEQ ID NO:2 is the vanB gene cluster sequence; SEQ ID NO:3 is the vanC gene sequence; SEQ ID NO:4 is the vanD gene cluster sequence) or to conserved regions of these target genes (e.g., SEQ ID NOS: 11, 12, and 13).

In general, the antisense molecules which hybridize to a conserved region of a target vancomycin resistance gene contain from about 18 to about 1500 nucleotides, more preferably from about 10 to about 30 nucleotides, and most preferably from about 20 to about 30 nucleotides.

In general, the anti-sense vancomycin resistance molecules are introduced to the organism by contacting the vancomycin resistant organism with at least one cassette (typically contained in a vector) comprising one or more "anti-sense vancomycin resistance molecules" under conditions to allow the vector to enter the organism and inhibit expression of one or more vancomycin resistance genes. In general, the vector comprises an expression cassette which permits expression of the anti-sense vancomycin resistance molecules in the organism. The preferred vectors are selected from the group consisting of: an enterococcal shuttle vector (e.g., see the Examples), an enterococcal bacteriophage (Merril CR, et al., *Proc Natl Acad Sci USA*, 1996, 93:3188-92); the nucleic acid portion of a peptide nucleic acid molecule (Good L, et al., *Nat Biotechnol,* 1998; 16:355-8); an enterococcal conjugative transposon or pheromone-responsive plasmid (Murray BE, *Emerg Infect Dis,* 1998, 4:37-47).

In certain embodiments such as those described in detail in the Examples, the cassette contains one or more copies of a *vanA* antisense molecule operatively coupled to a promoter, preferably, the same inducible promoter which drives expression of the *vanH*, *vanA*, and *vanX* resistance determinant, e.g., a *VanR*-responsive promoter such as the *vanH* promoter. As used herein, a *VanR*-responsive refers to a promoter which activates transcription in response to binding of a phosphorylated *VanR* protein.

Preferably, the *VanR*-responsive promoter is a *vanH* promoter ($P_{vanH}$) or a *vanR* promoter ($P_{vanR}$), each of which directs transcription of the genes of the vancomycin resistance operon found in several species. These *VanR*-responsive promoters activate transcription in response to binding of an activated *VanR* protein. These promoters include, in addition to the *VanR* binding sites, all other sequences required for efficient transcriptional activation of the gene or genes located downstream of the promoters. In general, these *VanR*-responsive promoters ($P_{vanH}$, $P_{vanR}$) include the 60 nucleotides immediately upstream (nucleotides -60 to -1) of the genes encoding a *VanR* protein or a *VanR* protein, which

sequences include a *VanR* binding site, and other sites which contribute to efficient *VanR*-responsive activation of gene transcription.

Other *VanR*-responsive promoters can be used to effect transcription of protein coding sequences. For example, alternative *VanR*-responsive promoters can be identified by searching databases of bacterial nucleotide sequences for sequences which have *VanR* binding sites in proximity to sites which contribute to efficient bacterial transcriptional activation, e.g. a consensus binding site for bacterial DNA polymerase. Such sites are well-known to one of ordinary skill in the art. *VanR*-responsive promoters can also be identified by genetic screening and cloning protocols that are standard in the art, as described in Sambrook. Further, non-natural *VanR* promoters can be prepared by combining a *VanR* binding site with the other nucleotide sequences which contribute to efficient bacterial transcriptional activity. Such synthetic or non-natural *VanR*-responsive promoters can be synthesized directly by chemical means, such as by use of an automated DNA synthesizer.

In an analogous manner, other embodiments can be prepared in which the expression cassette contains one or more copies of a different vancomycin resistance antisense molecule operatively coupled to a promoter which drives expression of the targeted antisense gene.

In yet another aspect of the invention, an alternative method for reducing vancomycin resistance is provided. According to this aspect of the invention, the method involves enhancing expression of a *VanR*-responsive promoter, such as a *vanH* promoter, in the organism to an amount sufficient to reduce vancomycin resistance in the organism, wherein the *vanH* promoter is not operatively coupled to a vancomycin resistance gene of the organism. As used herein, a "vancomycin resistance gene of the organism" refers to the gene in its native configuration contained within the genome of the organism, i.e., not isolated from the organism.

In certain preferred embodiments, the *vanH* promoter is operatively coupled to an antisense vancomycin resistance molecule, such as a *vanA* anti-sense molecule. More preferably, the *vanH* promoter (alone or operatively coupled to an antisense vancomycin resistance molecule) is contained in a cassette. Typically, the cassette is contained in a vector to facilitate transport into and out of the resistant organism. In a particularly preferred embodiment, the vector is an *enterococcal* vector and enhancing expression of the *vanH* promoter involves introducing the vector into the organism. Although not wishing to be bound to a particular theory or mechanism, it is believed that introducing the vector into the

organism results in expression of an amount of the *vanH* promoter sufficient that is sufficient to bind to phosphorylated *VanR* and thereby reduce vancomycin resistance in the organism. In further preferred embodiments, the *VanR*-responsive promoter, such as a *vanH* promoter is co-administered into the organism together with an antisense vancomycin resistance molecule operatively coupled to a *vanH* promoter.

According to still other aspects of the invention, compositions for use in accordance with the methods of the invention are provided. In certain embodiments, the compositions of the invention are isolated nucleic acids that hybridize under stringent conditions to a targeted vancomycin gene or a conserved region thereof, such as described in more detail below. In a particularly preferred embodiment, the isolated nucleic acid is vancomycin resistance gene sequence which has been cloned in the opposite direction (see, e.g., the Examples). Exemplary target genes and conserved regions thereof include the genes which are contained in the VanA resistance gene cluster (GenBank Accession No. M97297, SEQ ID NO:1), the VanB resistance gene cluster (GenBank Accession No. U35369, SEQ ID NO:2), the VanC resistance gene cluster (GenBank Accession No. L29638, SEQ ID NO:3), and the VanD resistance gene cluster (GenBank Accession No. AF130997, SEQ ID NO:4). The location of the individual genes in each gene cluster is set forth in each GenBank listing. Thus, the anti-sense molecules of the invention have sequences which are complementary, and therefore capable of hybridizing to the target genes identified herein, as well as to conserved and/or unique regions of these genes (e.g., by using routine skill to search nucleic acid databases such as GenBank to identify regions of the vancomycin resistance genes which are conserved and/or which are unique). In certain preferred embodiments, the anti-sense molecules of the invention hybridize to regions of the target gene which encode an active site or other which encodes an active site or other functional portion of the encoded protein (e.g., the active site of the ligase encoded by the vanA gene). Using such techniques, Applicants have identified the following nucleotide regions of representative target genes to which the anti-sense molecules can be designed to hybridize (i.e., the anti-sense molecules have complementary nucleotide sequences to the target genes or the selected regions).

SUMMARY TABLE

| SEQ ID NO | GENE/ACC NO | NUCLEOTIDE NOS | TARGETED SEQ NO |
|---|---|---|---|
| 5 | *vanS*/M97297 | 5657 to 5684 | 5'-ggtggcgcgggacttggatggcgattg-3' |
| 6 | *vanR*/M97297 | 4258 to 4287 | 5'ggcgcggatgattatataacgaagcccttt-3' |

| | | | |
|---|---|---|---|
| 7 | *vanA*/M97297 | 7719 to 7736 | 5'-cgagccggaaaaaggctc-3' |
| 8 | *vanA*/M97297 | 7339 to 7358 | 5'-ggctgcgatattcaaagctc-3' |
| 9 | *vanH*/M97297 | 6033 to 6059 | 5'-attactgtttatggatgtgagcaggat-3' |
| 10 | *vanX*/M97297 | 8343 to 8368 | 5'-gtggcttcaaaatcaagccatagccg-3' |
| 11 | VanB/U35369 | 5708 to 5725 | 5'-cgagccggaaaaaggctc-3' |
| 12 | VanB/U35369 | 5328 to 5347 | 5'-ggctgcgatattcaaagctc-3' |
| 13 | VanD/AF130997 | 4443 to 4462 | 5'-ggctgcgatattcaaagctc-3' |

It will be understood that anti-sense molecules which contain a few nucleotide residues (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) which hybridize to either side of the above-identified conserved nucleotide regions are embraced within the meaning of the anti-sense molecules disclosed and claimed herein for use in accordance with the methods of the invention.

According to still other aspects of the invention, cassettes containing the isolated nucleic acids of the invention, as well as vectors containing such nucleic acids and/or cassettes, also are provided. Preferably the cassettes further comprise a vancomycin-inducible promoter (e.g., a *VanR*-responsive promoter such as a *vanH* promoter) operatively coupled to one or more isolated nucleic acid molecules of the invention. In still other embodiments, isolated vancomycin resistant organisms containing any of the foregoing isolated nucleic acids, cassettes and/or vectors also are provided.

These and other embodiments and utilities of the invention will become more apparent in reference to the following drawings and detailed description of the preferred embodiments.

All references are incorporated in their entirety herein by reference.

## Brief Description of the Sequences

SEQ ID NO:1 -- The nucleic acid encoding the VanA resistance gene cluster of *Enterococcus faecium*. GenBank accession number M97297.

SEQ ID NO:2 -- The nucleic acid encoding the VanB resistance gene cluster of *Enterococcus faecalis*. GenBank accession number U35369.

SEQ ID NO:3 -- The nucleic acid encoding the VanC resistance gene cluster of *Enterococcus casseliflavus*. GenBank accession number L29638.

SEQ ID NO:4 -- The nucleic acid encoding the VanD resistance gene cluster of *Enterococcus faecium*. GenBank accession number AF130997.

SEQ ID NO:5 -- A conserved nucleic acid region of the *vanS* gene of the VanA gene cluster.

SEQ ID NO:6 -- A conserved nucleic acid region of the *vanR* gene of the VanA gene cluster.

SEQ ID NO:7 -- A conserved nucleic acid region of the *vanA* gene of the VanA gene cluster (nucleotides 7719 to 7736).

SEQ ID NO:8 -- A conserved nucleic acid region of the *vanA* gene of the VanA gene cluster (nucleotides 7339 to 7358).

SEQ ID NO:9 -- A conserved nucleic acid region of the *vanH* gene of the VanA gene cluster.

SEQ ID NO:10 -- A conserved nucleic acid region of the *vanX* gene of the VanA gene cluster.

SEQ ID NO:11 -- A conserved nucleic acid region of the vanB gene cluster (nucleotides 5708 to 5725).

SEQ ID NO:12 -- A conserved nucleic acid region of the vanB gene cluster (nucleotides 5328 to 5347).

SEQ ID NO:13 -- A conserved nucleic acid region of the vanD gene cluster.

SEQ ID NO:14 -- A 5' -PCR primer oligonucleotide sequence for the *vanH* promoter, used in conjunction with the primer of SEQ ID NO:15.

SEQ ID NO:15 -- A 3' -PCR primer oligonucleotide sequence for the *vanH* promoter, used in conjunction with the primer of SEQ ID NO:14.

SEQ ID NO:16 -- A 5' -PCR primer oligonucleotide sequence for the *vanA* gene, used in conjunction with the primer of SEQ ID NO:17.

SEQ ID NO:17 -- A 3' -PCR primer oligonucleotide sequence for the *vanA* gene, used in conjunction with the primer of SEQ ID NO:16.

SEQ ID NO:18 -- The nucleotide sequence of the *vanR* gene of the VanA gene cluster (SEQ ID NO:1).

SEQ ID NO:19 -- The nucleotide sequence of the *vanS* gene of the VanA gene cluster (SEQ ID NO:1).

SEQ ID NO:20 -- The nucleotide sequence of the *vanH* gene of the VanA gene cluster (SEQ ID NO:1).

SEQ ID NO:21 -- The nucleotide sequence of the *vanA* gene of the VanA gene cluster (SEQ ID NO:1).

SEQ ID NO:22 -- The nucleotide sequence of the *vanX* gene of the VanA gene cluster (SEQ ID NO:1).

SEQ ID NO:23 -- The nucleotide sequence of the *vanY* gene of the VanA gene cluster (SEQ ID NO:1).

SEQ ID NO:24 -- The nucleotide sequence of the *vanZ* gene of the VanA gene cluster (SEQ ID NO:1).

SEQ ID NO:25 -- A 3' -PCR primer oligonucleotide sequence for the *vanA* gene, used in conjunction with the primer of SEQ ID NO:16.

SEQ ID NO:26 -- The nucleotide sequence of the *vanRB* gene of the VanB gene cluster (SEQ ID NO:2).

SEQ ID NO:27 -- The nucleotide sequence of the *vanSB* gene of the VanB gene cluster (SEQ ID NO:2).

SEQ ID NO:28 -- The nucleotide sequence of the *vanYB* gene of the VanB gene cluster (SEQ ID NO:2).

SEQ ID NO:29 -- The nucleotide sequence of the *vanHB* gene of the VanB gene cluster (SEQ ID NO:2).

SEQ ID NO:30 -- The nucleotide sequence of the *vanB* gene of the VanB gene cluster (SEQ ID NO:2).

SEQ ID NO:31 -- The nucleotide sequence of the *vanXB* gene of the VanB gene cluster (SEQ ID NO:2).

SEQ ID NO:32 -- The nucleotide sequence of the *vanW* gene of the VanB gene cluster (SEQ ID NO:2).

SEQ ID NO:33 -- The nucleotide sequence of the *vanC-2* gene of the VanC gene cluster (SEQ ID NO:3).

SEQ ID NO:34 -- The nucleotide sequence of the *vanRD* gene of the VanD gene cluster (SEQ ID NO:4).

SEQ ID NO:35 -- The nucleotide sequence of the *vanSD* gene of the VanD gene cluster (SEQ ID NO:4).

SEQ ID NO:36 -- The nucleotide sequence of the *vanYD* gene of the VanD gene cluster (SEQ ID NO:4).

SEQ ID NO:37 -- The nucleotide sequence of the *vanHD* gene of the VanD gene cluster (SEQ ID NO:4).

SEQ ID NO:38 -- The nucleotide sequence of the *vanD* gene of the VanD gene cluster (SEQ ID NO:4).

SEQ ID NO:39 -- The nucleotide sequence of the *vanXD* gene of the VanD gene cluster (SEQ ID NO:4).

## Brief Description of the Drawings

**Figure 1.** A schematic showing the organization of genes in the VanA vancomycin resistance operon.

**Figure 2.** Schematic maps of the shuttle vectors and relevant cloning sites; Fig. 2A shows the parent vector, pAM401; Fig. 2B shows the restriction sites for the *vanH* promoter insertion into pAM401; Fig. 2C shows the restriction sites for the *vanA* antisense insertion *into vanH* promoter/pAM401 construct.

**Figure 3.** A schematic showing the proposed nucleic acid binding decoy mechanism with the introduction of a shuttle vector carrying the *vanH* promoter alone.

**Figure 4.** A schematic of the proposed mechanism-of-action of the pAM401-*vanH* promoter-*vanA* antisense recombinant shuttle vector.

## Detailed Description of the Invention

While vancomycin has been the mainstay of treatment for beta-lactam antibiotic-resistant enterococci, the increasing prevalence of vancomycin-resistant enterococci has prompted a continued search for new therapeutic approaches. In eukaryotic and prokaryotic systems, gene transfer has been used to define molecular pathogenesis as well as applied towards therapeutic ends. The elucidation of the genetic basis for vancomycin resistance has uncovered potential targets for a unique anti-drug resistance gene-based strategy. Particularly, the preferred embodiments of the present invention consist of a gene cassette comprised of the enterococcal *vanH* promoter and a single copy of a *vanA* antisense gene in the shuttle vector, pAM401. Using this invention, we have demonstrated the ability to increase the vancomycin susceptibility of a vancomycin-resistant *Enterococcus faecalis* by up to 32-fold.

According to one aspect of the invention, a method for reducing vancomycin resistance in a vancomycin-resistant organism is provided. The method involves introducing into the organism at least one "anti-sense vancomycin resistance molecule" under conditions to inhibit expression of a vancomycin resistance gene.

As used herein, "reducing vancomycin resistance" refers to enhancing the susceptibility of a vancomycin resistant organism to vancomycin to a statistically significant extent. In the embodiments illustrated in the Examples, the methods of the invention have

been used to increase the vancomycin susceptibility of a vancomycin-resistant *Enterococcus faecalis* by at least about 16-fold and up to about 32-fold compared to organisms which have not been so treated. These results demonstrate the utility of the invention for reducing vancomycin resistance in the particular organisms tested, as well as the feasibility of using the methods of the invention for treating other types of glycopeptide-resistant bacteria (e.g., VanB, VanC, and VanD type bacteria).

According to certain aspects of the invention, the methods involve inhibiting expression of a vancomycin resistance gene. As used herein, "inhibit expression" refers to inhibiting (i.e., reducing to a detectable extent) replication, transcription, and/or translation of a vancomycin gene since inhibition of any of these processes results in the inhibition of expression of a protein encoded by a vancomycin gene. Exemplary vancomycin-resistant organisms include the Gram-positive bacteria *Enterococcus faecium* and *Enterococcus faecalis* and other bacteria to which these organisms have the potential of transferring resistance determinants, given that VanA is a transferable form of resistance and that it could be transferred to other clinically significant pathogens such as *Streptococcus* species *Pneumococcus*, and *Staphylococcus* species. (See, e.g., Brisson-Noel A. Arthur, M. Courvalin P., "Evidence for natural gene transfer from Gram-positive cocci to *Escherichia coli*," *J. Bacteriol* 170:1739-1745, 1988).

Preferably, the vancomycin resistant organism is a Gram-positive bacteria and, more preferably, the organism is an *Enterococcus*.

Vancomycin resistance can take a variety of forms depending upon the nature of the gene(s) which mediates the resistance phenotype. Thus, exemplary vancomycin resistant organisms of the invention may exhibit one or more of the following phenotypes: VanA resistance, VanB resistance, VanC resistance, and VanD resistance.

VanA resistance is mediated by a gene cluster (SEQ ID NO:1) which includes seven genes: *vanR* (SEQ ID NO:18), *vanS* (SEQ ID NO:19), *vanH* (SEQ ID NO:20), *vanA* (SEQ ID NO:21), *vanX* (SEQ ID NO:22), *vanY* (SEQ ID NO:23), and *vanZ* (SEQ ID NO:24), as described in GenBank Accession No. M97297 (SEQ ID NO:1). VanB resistance is mediated by a gene cluster which includes seven genes: *vanRB* (SEQ ID NO:26), *vanSB* (SEQ ID NO:27), *vanYB* (SEQ ID NO:28), *vanHB* (SEQ ID NO:29), *vanB* (SEQ ID NO:30), *vanXB* (SEQ ID NO:31), and *vanW* (SEQ ID NO:32), as described in GenBank Accession No. U35369 (SEQ ID NO:2); VanC resistance is mediated by a *vanC-2* gene (SEQ ID NO:33), as described in GenBank Accession No. L29638 (SEQ ID NO:3); VanD resistance is mediated

by a gene cluster which includes at least six genes: *vanRD* (SEQ ID NO:34), *vanSD* (SEQ ID NO:35), *vanYD* (SEQ ID NO:36), *vanHD* (SEQ ID NO:37), *vanD* (SEQ ID NO:38), and *vanXD* (SEQ ID NO:39), as described in GenBank Accession No. AF130997 (SEQ ID NO:4). Although the Examples illustrate the application of the invention for treating *vanA* resistance, it is to be understood that the invention can be tailored to treating one or more types of antibiotic resistance to a vancomycin antibiotic by selecting antisense molecules and/or appropriate promoters which can be used to reduce expression of the resistance genes in the targeted organism.

In a preferred embodiment in which the vancomycin resistant organism is a VanA organism, the antisense vancomycin resistance molecule is selected from the group consisting of antisense molecules which hybridize under stringent conditions to these target genes or to conserved, unique, or functionally important regions of these target genes as described above. As used herein, such antisense molecules to these target genes are referred to as *vanA* anti-sense molecules, *vanR* antisense molecules, *vanS* anti-sense molecules, *vanH* anti-sense molecules, *vanX* anti-sense molecules, *vanY* anti-sense molecules, and *vanZ* anti-sense molecules, respectively. In a particularly preferred embodiment, the organism carries a VanA phenotype and the anti-sense vancomycin resistance molecule hybridizes under physiological conditions to the *vanA* target gene or to a conserved region of the *vanA* gene.

Additionally or alternatively, the vancomycin-resistant organism can be a VanB, VanC, and/or VanD resistant organism and the anti-sense vancomycin resistance molecule is selected which hybridizes under stringent conditions to these target genes (SEQ ID NO:2 is the VanB gene cluster sequence; SEQ ID NO:3 is the VanC gene sequence; SEQ ID NO:4 is the VanD gene cluster sequence) or to conserved regions of these target genes. In general, the antisense molecules are isolated molecules which hybridize to a conserved region of a target vancomycin resistance gene contain from about 18 to about 1500 nucleotides, more preferably from about 10 to about 30 nucleotides, and most preferably, from about 20 to about 30 nucleotides.

The nucleic acid molecules described herein preferably are isolated. As used herein with respect to nucleic acids, the term "isolated" means: (i) amplified *in vitro* by, for example, polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; (iii) purified, as by cleavage and gel separation; or (iv) synthesized by, for example, chemical synthesis. An isolated nucleic acid is one which is readily manipulable by recombinant DNA techniques well known in the art. Thus, a nucleotide sequence contained in a vector in which

5' and 3' restriction sites are known or for which polymerase chain reaction (PCR) primer sequences have been disclosed is considered isolated but a nucleic acid sequence existing in its native state in its natural host is not. An isolated nucleic acid may be substantially purified, but need not be. For example, a nucleic acid that is isolated within a cloning or expression vector is not pure in that it may comprise only a tiny percentage of the material in the cell in which it resides. Such a nucleic acid is isolated, however, as the term is used herein because it is readily manipulable by standard techniques known to those of ordinary skill in the art. An isolated nucleic acid as used herein is not a naturally occurring chromosome.

As used herein, the term "antisense oligonucleotide" or "antisense" describes an oligonucleotide that is oligoribonucleotide, oligodeoxyribonucleotide, modified oligoribonucleotide, or modified oligodeoxyribonucleotide which hybridizes under physiological conditions to DNA comprising a particular gene or to a messenger RNA (mRNA) transcript of that gene and, thereby, inhibits the transcription of that gene and/or the translation of that mRNA. The antisense molecules are designed so as to interfere with transcription or translation of a target gene upon hybridization with the target gene or transcript. Those skilled in the art will recognize that the exact length of the antisense oligonucleotide and its degree of complementarity with its target will depend upon the specific target selected, including the sequence of the target and the particular bases which comprise that sequence. It is preferred that the antisense oligonucleotide be constructed and arranged so as to bind selectively with the target under the physiological conditions of the target organism, i.e., to hybridize substantially more to the target sequence than to any other sequence in the target cell under physiological conditions. Based upon the sequences of nucleic acids encoding the vancomycin resistance proteins, or upon allelic or homologous genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention. In order to be sufficiently selective and potent for inhibition, such antisense oligonucleotides should comprise at least 10 and, more preferably, at least 15 consecutive bases which are complementary to the target, although in certain cases modified oligonucleotides as short as 7 bases in length have been used successfully as antisense oligonucleotides. (Wagner et al., *Nature Biotechnol.* 14:840-844, 1996). Most preferably, the antisense oligonucleotides comprise a complementary sequence of 20-30 bases.

Although oligonucleotides may be chosen which are antisense to any region of the gene or mRNA transcripts, in preferred embodiments the antisense oligonuleotides correspond to N-terminal or 5' upstream sites such as translation initiation, transcription initiation or promoter sites. In addition, 3'-untranslated regions may be targeted. Targeting to mRNA splicing sites has also been used in the art but may be less preferred if alternative mRNA splicing occurs. In addition, the antisense is targeted, preferably, to sites in which mRNA secondary structure is not expected (see, e.g., Sainio et al., *Cell Mol. Neurobiol.* 1994, 14(5):439-457) and at which proteins are not expected to bind. Finally, although the listed sequences may include cDNA sequences, one of ordinary skill in the art may easily derive the genomic DNA corresponding to the cDNA of a vancomycin resistance gene. Thus, the present invention also provides for antisense oligonucleotides which are complementary to the genomic DNA corresponding to nucleic acids encoding vancomycin resistance proteins. Similarly, antisense to allelic or homologous cDNAs and genomic DNAs are enabled without undue experimentation.

Exemplary U.S. patents which describe and claim antisense molecules for reducing gene expression include U.S. Patent Nos. 5,734,039; 5,783,683; 5,859,229; 5,858,987; 5,919,677; and 5,916,807; the entire contents of which patents are incorporated in their entirety herein by reference.

In one set of embodiments, the antisense oligonucleotides of the invention may be composed of "natural" deoxyribonucleotides, ribonucleotides, or any combination thereof. That is, the 5' end of one native nucleotide and the 3' end of another native nucleotide may be covalently linked, as in natural systems, via a phosphodiester internucleoside linkage. These oligonucleotides may be prepared by art recognized methods which may be carried out manually or by an automated synthesizer. They also may be produced recombinantly by vectors.

In preferred embodiments, however, the antisense oligonucleotides of the invention also may include "modified" oligonucleotides. That is, the oligonucleotides may be modified in a number of ways which do not prevent them from hybridizing to their target but which enhance their stability or targeting or which otherwise enhance their therapeutic effectiveness.

The term "modified oligonucleotide" as used herein describes an oligonucleotide in which (1) at least two of its oligonucleotides are covalently linked via a synthetic internucleoside linkage (i.e., a linkage rather than a phosphodiester linkage between the 5' end of one oligonucleotide and the 3' end of another nucleotide) and/or (2) a chemical group not

normally associated with nucleic acids has been covalently attached to the oligonucleotide. Preferred synthetic internucleoside linkages are phosphorothioates, alkylphosphonates, phosphorodithioates, phosphate esters, alkylphosphonothioates, phosphoramidates, carbamates, carbonates, phosphate triesters, acetamidates, carboxymethyl esters and peptides.

The term "modified oligonucleotide" also encompasses oligonucleotides with a covalently modified base and/or sugar. For example, modified oligonucleotides include oligonucleotides having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified oligonucleotides may include a 2'-O-alkylated ribose group. In addition, modified oligonucleotides may include sugars such as arabinose instead of ribose. The present invention, thus, contemplates pharmaceutical preparations containing modified antisense molecules that are complementary to and hybridizable with, under physiological conditions, nucleic acids encoding vancomycin resistance polypeptides, together with acceptable carriers to deliver these molecules into the target organism.

The compositions of the invention may be administered as part of a pharmaceutical composition to a mammal (e.g., humans, domestic animals, such as dogs, cats, livestock, such as horses, sheep, cows, pigs) hosting a vancomycin resistant organism. Such a pharmaceutical composition may include the antisense oligonucleotides in combination with any standard physiologically and/or pharmaceutically effective amount of the antisense oligonucleotides in a unit of weight or volume suitable for administration to a patient. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. The term "physiologically acceptable" refers to a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism. The characteristics of the carrier will depend on the rout of administration. Physiologically and pharmaceutically acceptable carriers include diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials which are well known in the art, as further described below.

The compositions of the invention also may be introduced into vancomycin resistant organisms which is ex vivo, i.e., not contained within a mammal. For example, the applications of such compositions include both treatment of vancomycin-resistant enterococci or other clinically significant pathogen infections and colonization including, for example: (1) *ex vivo* eradication of vancomycin-resistant enterococci from frequently colonized settings

(e.g., intensive care units, hemodialysis units, chronic care facilities); (2) *in vivo* clearance of vancomycin-resistant enterococci from colonized gastrointestinal or genitourinary tracts of human and animal subjects; and (3) primary or adjuvant therapy for vancomycin-resistant enterococcal infections. In certain embodiments, antisense oligonucleotides (e.g., a synthetic antisense DNA strand) are used as a means for delivering this motif into bacteria by delivering the genes which code for antisense RNA (e.g., by conjugation, transformation, or transduction with bacteriophage). Accordingly, the antisense motif and other anti-resistance determinant genetic elements of the invention (e.g., nucleic acid binding decoys, transdominant mutants, suicide genes, ribozymes etc.) may be introduced into enterococci via transconjugation or via recombinant bacteriophage.

As used herein, a "vector" may be any of a number of nucleic acids into which a desired sequence may be inserted by restriction and ligation for transport between different genetic environments or for expression in a host organism. Vectors are typically composed of DNA although RNA vectors are also available. Vectors include, but are not limited to, plasmids, phagemids and virus genomes. A cloning vector is one which is able to replicate autonomously or integrated in the genome or host cell, and which is further characterized by one or more endonuclease restriction sites at which the vector may be cut in a determinable fashion and into which a desired DNA sequence by be ligated such that the new recombinant vector retains its ability to replicate in the host cell. In the case of plasmids, replication of the desired sequence may occur many times as the plasmid increases in copy number within the host bacterium or just a single time per host before the host reproduces by mitosis. In the case of phage, replication may occur actively during a lytic phase or passively during a lysogenic phase. An expression vector is one into which a desired DNA sequence may be inserted by restriction and ligation such that it is operably joined to regulatory sequences and may be expressed as an RNA transcript. Vectors may further contain one or more marker sequences suitable for use in the identification of cells which have or have not been transformed or transfected with the vector. Markers include, for example, genes encoding proteins which increase or decrease either resistance or sensitivity to antibiotics or other compounds, genes which encode enzymes whose activities are detectable by standard assays known in the art (e.g., β-galactosidase, luciferase or alkaline phosphatase), and genes which visibly affect the phenotype of transformed or transfected cells, hosts, colonies or plaques (e.g., green fluorescent protein). Preferred vectors are those capable of autonomous replication and

expression of the structural gene products present in the DNA segments to which they are operably joined.

As used herein, a coding sequence and regulatory sequences are said to be "operably" joined when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory sequences. If it is desired that the coding sequences be translated into a functional protein, two DNA sequences are said to be operably joined if induction of a promoter in the 5' regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a promoter region would be operably joined to a coding sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide.

The precise nature of the regulatory sequences needed for gene expression may vary between species or cell types, but shall in general include, as necessary, 5' non-transcribed and 5' non-translated sequences involved with the initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribed regulatory sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined gene. Regulatory sequences may also include enhancer sequences or upstream activator sequences as desired. The vectors of the invention may optionally include 5' leader or signal sequences. The choice and design of an appropriate vector is within the ability and discretion of one of ordinary skill in the art.

Expression vectors containing all the necessary elements for expression are commercially available and known to those skilled in the art. See, e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. Cells are genetically engineered by the introduction into the cells of heterologous DNA (RNA) encoding a vancomycin polypeptide or fragment or variant thereof. That heterologous DNA (RNA) is placed under operable control of transcriptional elements to permit the expression of the heterologous DNA in the host bacterium.

The vancomycin resistance operons of a targeted organism include, e.g., the naturally occurring operon of *Enterococcus faecium*, or such operons which are substantially identical thereto, e.g., homologs of the vancomycin resistance operon of *Enterococcus faecium* from other species, functionally equivalent variant of the vancomycin resistance operon containing variants of the genes which constitute the naturally occurring operon. Such variants may be sequence variants, e.g., containing conservative substitutions of amino acids and the like as defined herein, or may be different genes which have the same or a similar function as one of the genes found in the naturally-occurring vancomycin operon. For example, the *ddlB* gene of *E. coli* encodes a protein that exhibits similar properties of the VanA protein as discussed below. Thus, a preferred vancomycin resistance operon of a targeted organism typically includes a *vanH* gene, a *ddlB* gene and a *vanX* gene.

The VanA protein product has two activities: a D-Ala-D-hydroxybutyrate depsipeptide ligase activity (Bugg et al., *Biochemistry* 30:2017-2021, 1991). VanA shares 28% amino acid identity with an *E. coli* enzyme, DdlB, which is a D-Ala-D-Ala dipeptide ligase. Two point mutants of DdlB recently have been reported that exhibit depsipeptide ligase activity (S150A and Y126F; Shi & Walsh, *Biochemistry* 34:2768-2776, 1995; Park et al., *Biochemistry*, 1996, *in press*). Thus, these mutants appear to be functional homologs of VanA. Other functional homologs include, for example, genes encoding a VanA or DdlB protein that are present in other vancomycin operons, including such genes present in other species which encode vancomycin resistance. For example, other vancomycin resistant strains of bacteria (i.e., not *Enterococci* which have a VanA operon) have modified Ddl proteins which serve to make depsipeptide termini directly. Non-VanA vancomycin resistance operons such as the VanB vancomycin resistance operon, contain functionally equivalent VanA homologs. Other functional homologs, either natural or non-natural, are also embraced by the invention.

In general, the anti-sense vancomycin resistance molecules are introduced to the organism by contacting the vancomycin resistant organism with at least one cassette, preferably contained in a vector, which cassette comprises one or more "anti-sense vancomycin resistance molecules" operably coupled to a promoter (e.g., a *VanR* response promoter). The cassette is contacted with the organism under conditions which allow the cassette and/or vector to enter the organism and inhibit expression of one or more vancomycin resistance genes. Typically, the vector comprises an expression cassette which permits expression of the anti-sense vancomycin resistance molecules in the organism. The preferred vectors are selected from the group consisting of: an enterococcal shuttle vector

(e.g., see the Examples), an enterococcal bacteriophage (Merril CR, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S, Adhya S, "Long-Circulating Bacteriophage as Antibacterial Agents," *Proc Natl Acad Sci USA*, 1996; 93:3188-92); the nucleic acid portion of a peptide nucleic acid molecule (Good L, Nielsen PE, "Antisense Inhibition of Gene Expression in Bacteria by PNA Targeting To mRNA," *Nat Biotechnol* 1998; 16:355-8); an enterococcal conjugative transposon or pheromone-responsive plasmid (Murray BE, "Diversity Among Multidrug-Resistant Enterococci," *Emerg Infect Dis* 1998; 4:37-47).

In certain embodiments such as those described in detail in the Examples, the cassette contains one or more copies of a *vanA* antisense molecule, e.g., in tandem, operatively coupled to a promoter, preferably, the same inducible promoter which drives expression of the *vanA* resistance determinant, e.g., a *VanR*-responsive promoter such as the *vanH* promoter. As used herein, a *VanR*-responsive refers to a promoter which activates transcription in response to binding of an activated *VanR* protein. These promoters include, in addition to the *VanR* binding site, all other sequences required for efficient transcriptional activation of the gene or genes located downstream of the promoters. In an analogous manner, other embodiments can be prepared in which the expression cassette contains one or more copies of a different vancomycin antisense molecule operatively coupled to a promoter which drives expression of the targeted antisense gene.

In yet another aspect of the invention, an alternative method for reducing vancomycin resistance is provided. According to this aspect of the invention, the method involves enhancing expression of a *VanR*-responsive promoter (e.g., a *vanH* promoter) in the organism to an amount sufficient to reduce vancomycin resistance in the organism, wherein the *vanH* promoter is not operatively coupled to a vancomycin resistance gene of the organism. As used herein, a "vancomycin resistance gene of the organism" refers to the gene in its native configuration contained within the genome of the organism, i.e., not isolated from the organism or attached to nucleic acid which is not contained within the genome of the organism.

In certain preferred embodiments, the *VanR*-responsive promoter is operatively coupled to an antisense vancomycin resistance molecule, such as a *vanA* anti-sense molecule. More preferably, the *VanR*-responsive promoter (alone or operatively coupled to an antisense vancomycin resistance molecule) is contained in a cassette. Typically, the cassette is contained in a vector to facilitate transport into and out of the resistant organism. In a particularly preferred embodiment, the vector is an *enterococcal* vector and enhancing

expression of the *VanR*-responsive promoter involves introducing the vector into the organism. An exemplary cassette, vector and process for introducing the cassette into a vancomycin resistant organism and representative experimental evidence showing the efficacy of the claimed methods for reducing antibiotic resistance in a vancomycin resistant organism are described in the Examples.

Although not wishing to be bound to a particular theory or mechanism, it is believed that introducing the vector into the organism results in expression of an amount of the *VanR*-responsive promoter (e.g., a *vanH* promoter) that is sufficient to bind to phosphorylated *VanR* and thereby reduce vancomycin resistance in the organism by competitively sequestering the phosphorylated *VanR* protein.

According to still other aspects of the invention, compositions for use in accordance with the methods of the invention are provided. In certain embodiments, the compositions of the invention are isolated nucleic acids that hybridize under stringent conditions to a targeted vancomycin gene or a conserved region thereof, such as described in more detail below. In a particularly preferred embodiment, the isolated nucleic acid is vancomycin resistance gene sequence which has been cloned in the opposite direction (see, e.g., the Examples). Exemplary target genes and conserved regions thereof include the genes which are contained in the *vanA* resistance gene cluster (GenBank Accession No. M97297, SEQ ID NO:1), the *vanB* resistance gene cluster (GenBank Accession No. U35369, SEQ ID NO:2), the *vanC* resistance gene (GenBank Accession No. L29638, SEQ ID NO:3), and the *vanD* resistance gene cluster (GenBank Accession No. AF130997, SEQ ID NO:4). The location of the individual genes in each gene cluster is set forth in each GenBank listing. Thus, the anti-sense molecules of the invention have sequences which are complementary, and therefore capable of hybridizing to the target genes identified herein, as well as to conserved and/or unique regions of these genes (e.g., by using routine skill to search nucleic acid databases such as GenBank to identify regions of the vancomycin resistance genes which are conserved and/or which are unique). In certain preferred embodiments, the anti-sense molecules of the invention hybridize to regions of the target gene which encode an active site or other which encodes an active site or other functional portion of the encoded protein (e.g., the active site of the ligase encoded by the *vanA* gene). Using such techniques, Applicants have identified the following nucleotide regions of representative target genes to which the anti-sense molecules can be designed to hybridize (i.e., the anti-sense molecules have complementary nucleotide sequences to the target genes or the selected regions).

SUMMARY TABLE

| SEQ ID NO | GENE/ACC NO | NUCLEOTIDE NOS | TARGETED SEQ NO |
|---|---|---|---|
| 5 | *vanS*/M97297 | 5657 to 5684 | 5'-ggtggcgcgggacttggatggcgattg-3' |
| 6 | *vanR*/M97297 | 4258 to 4287 | 5'ggcgcggatgattatataacgaagccccttt-3' |
| 7 | *vanA*/M97297 | 7719 to 7736 | 5'-cgagccggaaaaaggctc-3' |
| 8 | *vanA*/M97297 | 7339 to 7358 | 5'-ggctgcgatattcaaagctc-3' |
| 9 | *vanH*/M97297 | 6033 to 6059 | 5'-attactgtttatggatgtgagcaggat-3' |
| 10 | *vanX*/M97297 | 8343 to 8368 | 5'-gtggcttcaaaatcaagccatagccg-3' |
| 11 | vanB/U35369 | 5708 to 5725 | 5'-cgagccggaaaaaggctc-3' |
| 12 | vanB/U35369 | 5328 to 5347 | 5'-ggctgcgatattcaaagctc-3' |
| 13 | vanD/AF130997 | 4443 to 4462 | 5'-ggctgcgatattcaaagctc-3' |

It will be understood that anti-sense molecules which contain a few nucleotide residues (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) which hybridize to either side of the above-identified conserved nucleotide regions are embraced within the meaning of the anti-sense molecules disclosed and claimed herein for use in accordance with the methods of the invention.

The term "stringent conditions" as used herein refers to parameters with which the art is familiar. More specifically, stringent conditions, as used herein, refers to hybridization at 65°C in hybridization buffer (3.5 x SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% Bovine Serum Albumin, 2.5mM $NaH_2PO_4$ (pH7), 0.5% SDS, 2mM EDTA). SSC is 0.15M sodium chloride/0.15M sodium citrate, pH7; SDS is sodium dodecyl sulphate; and EDTA is ethylenediaminetetracetic acid. After hybridization, the membrane upon which the DNA is transferred is washed at 2 x SSC at room temperature and then at 0.1 x SSC/0.1 x SDS at 65°C.

There are other conditions, reagents, and so forth which can be used, which result in a similar degree of stringency. The skilled artisan will be familiar with such conditions, and thus they are not given here. It will be understood, however, that the skilled artisan will be able to manipulate the conditions in a manner to permit the clear identification of homologs and alleles of nucleic acids encoding proteins of the invention. The skilled artisan also is familiar with the methodology for screening cells and libraries for expression of such molecules which then are routinely isolated, followed by isolation of the pertinent nucleic acid molecule and sequencing.

According to still other aspects of the invention, cassettes containing the isolated nucleic acids of the invention, as well as vectors containing such nucleic acids and/or cassettes, also are provided. Preferably the cassettes further comprise a vancomycin-inducible promoter (e.g., a *VanR*-responsive promoter such as a *vanH* promoter) operatively coupled to one or more isolated nucleic acid molecules of the invention. In still other embodiments, isolated vancomycin resistant organisms containing any of the foregoing isolated nucleic acids, cassettes and/or vectors also are provided.

"Co-administering," as used herein, refers to administering simultaneously two or more compounds (constructs) of the invention (e.g., the *VanR*-responsive promoter, such as a *vanH* promoter, and an antisense vancomycin resistance molecule operatively coupled to a *vanH* promoter), as an admixture in a single composition, or sequentially, close enough in time so that the compounds may exert an additive or even synergistic effect, i.e., on reducing vancomycin resistance.

The invention will be more fully understood by reference to the following examples. These examples, however, are merely intended to illustrate the embodiments of the invention and are not to be construed to limit the scope of the invention.

## Examples

*Plasmids*

The parent shuttle plasmid used in the test vector constructs was pAM401 (American Type Culture Collection, Rockville, MD) (Wirth, et al., *J. Bacteriol.*, 1986;165:831-836) . This plasmid is a high copy shuttle vector containing both Gram-negative bacillary (*Eschericia coli*) and enterococcal (*Enterococcus faecalis*) elements necessary for replication in these two bacterial types (Figure 2). To aid in selection of appropriately transformed clones, this plasmid also contains tetracycline and chloramphenicol resistance genes.

The cloning vector, pAMP1 (Gibco BRL, Rockville, MD), was also employed for the cloning of polymerase chain reaction-amplified fragments.

*Construction of Recombinant Enterococcal Shuttle Vectors*

The structures of the recombinant pAM401 shuttle vectors, including their pertinent restriction sites and vector constituents, are outlined in Figure 2 (Wirth, et al., *J Bacteriol*, 1986, 165:831-6). To construct a pAM401 shuttle vector containing the *vanH* promoter alone, *vanHP* was removed from pAMP1-*vanHP* using Xba I and Sal I restriction enzymes and ligated into pAM401 pre-digested with the same enzymes with the resultant pAM401-*vanHP*

shuttle vector (Figure 2). To produce the pAM401-*vanHP-vanA* antisense, *vanA* was digested out of pAMP1-*vanA* antisense with Xho I and Sal I and cloned into the Sal I site in pAM401-*vanHP* in the anti-coding direction.

*Bacterial Strains*

Vancomycin-resistant *Enterococcus faecalis* strains, designated A407 and A403, were VanA phenotype clinical isolates obtained from E. Cercenada (Hospital General Gregorio Marañón, Madrid, Spain). A1221 is a VanA strain of *Enterococcus faecium* resulting from the transconjugation with a VanA strain of *Enterococcus faecalis* (A312) obtained from F. Tenover (Centers for Disease Control, Atlanta, GA). These strains were identified as *Enterococcus faecalis* or *faecium* by the use of API-Rapid Strep Strips (bioMeriux Vitex, Inc., Hazelwood, MO). The presence of the *vanA* genotype was confirmed by DNA probe analysis as previously described (Eliopoulos, et al., *Antimicrob. Agents Chemother.*, 1998, 42:1088-92).

Vancomycin susceptibilities were determined by the National Committee for Clinical Laboratory Standards agar dilution method (National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M7-A4. Wayne, PA: NCCCLS, 1997). Commercially prepared competent DH5-alpha *Eschericia coli* (Gibco BRL, Rockville, MD) were also used in the cloning and sub-cloning of the vectors via a standard transformation protocol (Sambrook, et al., In:*Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press. 1989; 1.74).

*Antibiotics, Culture Media, Cloning Reagents*

Vancomycin and other antimicrobial agents were purchased from Sigma (St. Louis, MO). Restriction and modifying enzymes were obtained from Promega (Madison, WI) and New England BioLabs, Inc. (Beverly, MA). *Eschericia coli* were grown in Luria-Bertani medium and enterococci were grown on Mueller-Hinton or Blood-agar medium. Plasmid preparations were performed using Promega Wizard DNA Purification systems (Madison, WI).

*vanH Promoter and vanA Antisense Construction*

An approximate 450 base-pair fragment containing the *vanH* promoter - previously described to be necessary for expression of *vanH, -A*, and *–X* - was amplified using genomic DNA from a known strain of VanA strain *Enterococcus faecium* (A1221) as a template (Arthur, et al., *J. Bacter.*, 1992, 174:2582-2591). 5' and 3' primers were synthesized by

Gibco BRL (Rockville, MD). The primer sequences for the respective 5' and 3' *vanH* promoter primers as follows:

5'-CUA CUA CUA CUA CGA ATT CAA GAA CAC TGG-3' (SEQ ID NO:14)

5'-CAU CAU CAU CAU CCA ACC CTT TCT GTG AAA GGC ACC-3' (SEQ ID NO:15)

Polymerase chain reaction amplification was conducted through the use of a Perkin-Elmer 9600 thermocycler for 30 cycles of 94°C, 55°C, and 72°C for 30 seconds each. The resulting amplification product, termed *vanHP* (*vanH* promoter) was then subcloned into the plasmid, pAMP1 (Gibco BRL, Rockville, MD), using the Cloneamp™ (Gibco BRL, Rockville, MD) cloning protocol.

The *vanA* gene was amplified using the following primer pair and subcloning the product into pAMP1 to create a plasmid designated pAMP1-*vanA* antisense:

5'-CUA CUA CUA CUA CTC GAG GCT TAT CAC CCC TTT AAC GC-3' (SEQ ID NO:16)

5'-CAU CAU CAU CAU GGA GAC AGG AGC ATG AAT AG-3' (SEQ ID NO:17)

The polymerase chain reaction with these primers consisted of 30 cycles of 94° C, 55°C, and 72°C for 35 seconds each.

*Enterococcal Electroporation*

Transformation of the *Enterococcus faecalis* strains with pAM401, pAM401-*vanHP*, or pAM401-*vanHP-vanA* antisense was accomplished via electroporation with a Biorad Gene Pulser™ (Friesenegger, et al., *FEMS Microbiol. Letter*, 1991;79:323-328) . In this procedure, 40 ul of electrocompetent enterococci were combined in a sterile 0.1 cm electroporation cuvette with 2 µl of purified plasmid DNA. The electroporation apparatus settings were 1.50 volts and 400 ohms. Under these conditions, resultant time constants are typically in the 9 millisecond range.

*Vancomycin Susceptibility Assays: Agar and Broth Dilutions*

Vancomycin susceptibilities were determined using the standard National Committee for Clinical Laboratory Standards (NCCLS) agar dilution protocol (National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M7-A4. Wayne, PA: NCCCLS, 1997). In this assay, the test antibiotic, in this case, vancomycin, was incorporated into Mueller Hinton II agar medium (Becton Dickenson) at two-fold dilutions ranging from concentrations of 0 µg/ml up to 512 µg /ml. The agar was then poured into respective sterile plates. Bacterial strains were then inoculated onto the agar plates and incubated at 35°C overnight. The

minimum inhibitory concentration (MIC) was then determined by the lowest concentration of antibiotic that completely inhibited colony growth.

*Gene Expression-RT-PCR*

A single colony of A407 with the pAM401-*vanHP-vanA* antisense construct was grown in brain-heart infusion (BHI) liquid media with sub-inhibitory concentrations of vancomycin (1 μg/ml) and chloramphenicol (10 μg/ml). Bacterial RNA was prepared using the Qiagen RNeasy® protocol for the isolation of total RNA (Qiagen Inc. Valencia, CA) modified to incorporate a step of treatment with RNAse free DNAse applied directly on the QIAamp® column (both Qiagen Inc. Valencia, CA). Then a modified Titan™ One tube RT-PCR protocol (Roche molecular biochemicals, Indianapolis, IN) was followed. The samples were then reverse transcribed and amplified by one-step RT-PCR. Each reaction mix contained template RNA (5μg), enzyme (either Titan enzyme mix, reverse and forward PCR primers and buffer components recommended for optimal enzyme activity. The forward (5'-CUA CUA CUA CUA CTC GAG GCT TAT CAC CCC TTT AAC GC -3' -SEQ ID NO:16) and the reverse primer (5'-CGA ATA CCG CAA GCG ACA G-3' -SEQ ID NO:25) were designed to amplify a 1.1 kb bacterial RNA sequence. The RT reaction was performed at 45°C for 60 min, followed by PCR in a Perkin Elmer Model 9600 Thermal Cycler with the following thermal profile: Initial denaturation: 95°C for 3 min then 35 cycles of denaturation (93°C, 15 s), annealing (55°C, 30 s), elongation (68°C, 70 s) and a final extension step (72°C, 7 min). Amplification products were analyzed by gel electrophoresis.

Results

*Changes in Vancomycin Phenotypic Susceptibility*

The vancomycin susceptibility of a *vanA Enterococcus faecalis* strain, A407, was assessed after electroporation with either pAM401; pAM401-*vanHP*; or pAM401-*vanHP-vanA* antisense. While the vancomycin minimum inhibitory concentration (MIC) remained at 128 μg/ml in A407 containing the pAM401 shuttle vector alone, the introduction of pAM401 with the *vanH* promoter decreased the vancomycin MIC to 16 – 32 μg/ml. The vancomycin MIC was further decreased in response to the pAM401 containing both the *vanH* promoter and the *vanA* antisense, typically in the 8 μg/ml range.

*VanH promoter effect on vancomycin resistance*

The p*VanR* binding domain within the *vanH* promoter has previously been characterized and consists of an approximate 80 bp region that is considered to have the capacity to bind multiple p-*VanR* molecules (Holman, et al., *Biochemistry*, 1994, 33:4625-

31). Therefore, it was reasoned that the introduction of an exogenous *vanH* promoter cloned into a recombinant enterococcal shuttle vector could increase the vancomycin susceptibility of a target VanA enterococcal isolate through the binding and sequestration of p*VanR* from the native *vanH* promoter. As an initial test of this hypothesis, pAM401 enterococcal shuttle vectors with or without the *vanH* promoter were constructed and electroporated into a VanA strain of *E. faecalis* (A407). The successful transfer of the vectors by electroporation was confirmed through the purification of shuttle vector plasmids from the transformants followed by restriction digest analysis as well as by dideoxy-sequencing. To confirm that MIC changes in the transformants were not related to the loss of the VanA operon, the retention of the resistance determinant gene cluster was confirmed by the polymerase chain reaction (PCR) amplification of relevant genes.

Using both agar and broth dilution methods to determine antibiotic susceptibilities after shuttle vector electroporation, the vancomycin MIC of A407 enterococci transformed with the shuttle vector containing the *vanH* promoter (pAM401-*vanHP*) demonstrated a four-fold reduction in the MIC from 256 μg/mL to 64 μg/mL. In contrast and as expected, control A407 enterococci transformed with the pAM401 vector alone maintained the baseline (MIC of 256 μg/mL) resistance phenotype.

To further support that the vancomycin-resistance phenotypic changes seen with the transformation of pAM401-*vanHP* were due to a transcriptional activator binding decoy effect, the p*VanR* binding domain portion of the *vanH* promoter was amplified and cloned into pAM401 (pAM401-p*VanR*-BD+). As a control, a shuttle vector containing a mutant p*VanR* binding domain-deficient *vanH* promoter (pAM401-p*VanR*-BD-) was also constructed. Consistent with the phenotypic effects seen with the entire *vanH* promoter, the transfer of the p*VanR* binding domain (pAM401-p*VanR*-BD+) into A407 enterococci similarly resulted in a four-fold decrease in the vancomycin MIC to 64 μg/mL. As predicted, no vancomycin susceptibility change resulted from the introduction of the pAM401-p*VanR*-BD- vector.

*Effects of vanH promoter-driven vanA antisense RNA expression*

Recombinant pAM401 shuttle vectors were then created which contained a gene cassette consisting of the *vanH* promoter and downstream *vanA* antisense gene (pAM401-*vanHP-vanA* antisense), a configuration in which antisense expression would thus be upregulated in parallel that of the native VanA operon in the presence of vancomycin. A control vector that expressed *vanH* promoter-driven *vanA* sense transcripts was also cloned

(pAM401-*vanHP*-vanA sense) and was electroporated into respective A407 VanA *E. faecalis*. The expression of the *vanH* promoter-*vanA* coding and antisense messenger RNA were confirmed by reverse transcriptase PCR (RT-PCR). In A407 *E. faecalis* electroporated with pAM401-*vanHP-vanA* antisense, the vancomycin MIC was reduced to a susceptible range, from 256 μg/mL to 2 μg/mL. As predicted, the MIC of A407 transformed with pAM401-*vanHP-vanA* sense remained at the baseline level of 256 μg/mL.

Discussion

A gene cassette targeting a key antibiotic resistance determinant of the clinically relevant Gram-positive bacterium, *Enterococcus*, has been constructed and consists of the enterococcal *vanH*-promoter driving the expression of a *vanA* antisense gene introduced in an enterococcal shuttle vector. The target gene, *vanA*, is a highly conserved component of a gene cluster that confers high-level resistance to vancomycin, a pivotal antibiotic used to treat infections caused by *Enterococcus* resistant to beta-lactam antibiotics. The *vanH* promoter employed in this construct is the same inducible enterococcal promoter which drives expression of the *vanA* resistance determinant expression (Figure 3). In such an arrangement, where both the resistance and anti-resistance determinant expression are driven by the same inducible promoter, the enterococcal transcriptional factor, phosphorylated *VanR* (p*VanR*), which induces the *vanH* promoter (Arthur, et al., *J. Bacter.*, 1992, 174:2582-2591), is at the same time, sequestrated from the native *vanH* promoter, but also allows for induction of the anti-*vanA* antisense in parallel with the expression of the *vanHAX*. In short, this gene cassette inhibits vancomycin resistance both by an inducible antisense mechanism as well as by functioning as a transcriptional factor binding decoy (Figure 4). Reflective of such a dual mechanism, recombinant shuttle vectors containing the *vanH* promoter or the p*VanR* binding domain effected a partial restoration of vancomycin susceptibility, while full restoration of vancomycin susceptibility resulted with the introduction of a vector containing both *vanH* promoter and *vanA* antisense gene. More specifically, the introduction of a shuttle vector containing the *vanH* promoter alone into a vancomycin-resistant, *vanA*-containing *Enterococcus faecalis* resulted in up to a 16-fold reduction of the minimum inhibitory concentration for vancomycin while a shuttle vector containing both *vanH* promoter and *vanA* antisense increased vancomycin susceptibility even further (approximately 32-fold).

Given the increasingly important role of drug-resistant Gram-positive bacteria such as vancomycin-resistant *Enterococcus* as a cause of significant human disease, combined with a

dearth of effective pharmacological therapeutic options for this pathogen, novel strategies as described above, have several potential applications for (1) the treatment primary infections (2) the eradication of vancomycin-resistant *Enterococcus* from areas which are frequently colonized (e.g. intensive care units, dialysis units, individual patient's bowel flora, the agricultural setting) and (3) as a laboratory tool for the study of antibiotic resistance gene function and pathogenesis.

Recombinant shuttle vectors which target other genes in the *vanA* operon such as *vanX*, as well as polycistronic vectors which contain genetic elements designed to interfere with multiple VanA operon functions (e.g. *vanA, vanH*, and *vanX*), can be constructed using routine experimentation and no more than ordinary skill in the art. Given that an operon analogous to that associated with the VanA phenotype also forms the genetic basis for class B (VanB) vancomycin resistance, analogous compositions against Class B (VanB), as well as other classes of vancomycin resistance operons and genes can be developed as described above. For example, a *vanX* antisense strategy analogous to the vanA antisense strategy was also tested, resulting in lowering vancomycin MICs to the 2 μg/ml range.

Such compositions optimally include gene delivery systems such as bacteriophage, highly efficient transconjugative plasmids, and peptide-nucleic acids.

Deatailed Description of the Drawings

**Figure 1.** The VanA vancomycin resistance operon. *vanR* represents a response regulator which, after phosphorylation, activates the *vanH* promoter which results in activation of *vanH, vanA*, and *vanX* transcription; v*anS*, a signal sensor, is responsible for the inducibility of the operon by glycopeptide antibiotics;; the *vanH* gene product is a dehydrogenase that generates lactate from pyruvate; *vanA* codes for a ligase which preferentially synthesizes D-ala-D-lac; *vanX* codes for a dipeptidase which degrades the native D-ala-D-ala produced by the wildtype ligase; *vanY* is a carboxypeptidase which removes terminal alanines; *vanZ* is responsible for increased resistance to teicoplanin.

**Figure 2.** Maps of the shuttle vectors and relevant cloning sites. (A) The parent vector, pAM401. This vector is composed of both *Enterococcus faecalis* (shaded half on right) and *Eschericia coli* (bold portion on left) components. The *cat* region is the chloramphenicol acetyl-transferase gene. The *tet* region is the tetracycline resistance gene. (B) The *vanH* promoter insertion. (C) The *vanA* antisense insertion.

**Figure 3.** The proposed nucleic acid binding decoy mechanism by which the observed vancomycin minimum inhibitory concentrations are reduced with the introduction of the pAM401 shuttle vector with the *vanH* promoter alone.

**Figure 4.** A schematic of the proposed mechanism-of-action of the pAM401-*vanH* promoter-*vanA* antisense recombinant shuttle vector.

All terms used herein have their conventional meaning unless otherwise indicated.

All patents and other documents disclosed in this application are incorporated in their entirety herein by reference.

While the invention has been described with respect to certain embodiments, it should be appreciated that many modifications and changes may be made by those of ordinary skill in the art without departing from the spirit of the invention. It is intended that such modification, changes and equivalents fall within the scope of the following claims.

What is claimed is followed by the Abstract and a Sequence Listing.

We claim:

## Claims

1. A method for reducing vancomycin resistance in a vancomycin-resistant organism comprising:

introducing into the organism at least one anti-sense vancomycin resistance molecule under conditions to inhibit expression of a vancomycin resistance gene.

2. The method of claim 1, wherein the vancomycin resistant organism is selected from the group consisting of the Gram-positive bacteria , *Enterococcus faecalis* and *Enterococcus faecium*, and other Gram-positive bacteria such as *Staphylococcus species*, and *Streptococcus species*, to which these organisms have the potential of transferring resistance determinants.

3. The method of claim 1, wherein the vancomycin resistant organism is a Gram-positive bacteria.

4. The method of claim 3, wherein the Gram-positive bacteria is an enterococcus.

5. The method of claim 1, wherein the vancomycin resistant organism is selected from the group consisting of a VanA resistant organism, a VanB resistant organism, a VanC resistant organism, and a VanD resistant organism.

6. The method of claim 1, wherein the vancomycin resistant organism is a vanA resistant organism and the anti-sense vancomycin resistance molecule is selected from the group consisting of a *vanA* anti-sense molecule, a *vanR* antisense molecule, a *vanS* anti-sense molecule, a *vanH* anti-sense molecule, a *vanX* anti-sense molecule, a *vanY* anti-sense molecule and a *vanZ* anti-sense molecule.

7. The method of claim 1, wherein the vancomycin resistant organism is a VanB resistant organism and the anti-sense vancomycin resistance molecule is selected from the group consisting of a *vanRB* anti-sense molecule, a *vanSB* anti-sense molecule, a *vanYB* anti-sense molecule, a *vanW* anti-sense molecule, a *vanHB* anti-sense molecule, and a *vanXB* anti-sense molecule.

8. The method of claim 1, wherein the anti-sense vancomycin resistant organism is a VanC resistant organism.

9. The method of claim 1, wherein the vancomycin resistant organism is a VanD resistant organism and the anti-sense vancomycin resistance molecule is selected from the group consisting of a *vanD* anti-sense molecule, a *vanRD* anti-sense molecule, a *vanSD* anti-sense molecule, a *vanYD* anti-sense molecule, a *vanHD* anti-sense molecule, and a *vanXD* anti-sense molecule.

10. The method of claim 1, wherein the anti-sense vancomycin resistance molecule is a *vanA* antisense molecule selected from the group consisting of:

an antisense molecule that hybridizes to the complete *vanA* gene sequence; and

an antisense molecule that hybridizes to a conserved region of the *vanA* gene sequence.

11. The method of claim 10, wherein the *vanA* antisense molecule hybridizes to a conserved region of the *vanA* gene including from 10 to 30 nucleotides.

12. The method of claim 11, wherein the *vanA* gene encodes an enzyme and the *vanA* antisense molecule hybridizes to a region of the *vanA* gene which encodes an active site of the ligase.

13. The method of claim 1, wherein introducing the anti-sense vancomycin resistance molecule comprises contacting the vancomycin resistant organism with at least one vector comprising one or more "anti-sense vancomycin resistance molecules" under conditions to allow the vector to enter the organism and inhibit expression of one or more vancomycin resistance genes.

14. The method of claim 13, wherein the vector is selected from the group consisting of: an enterococcal shuttle vector, an enterococcal or any other species or strain of bacteriophage; the nucleic acid portion of a peptide nucleic acid molecule; an enterococcal conjugative transposon or a pheromone-responsive plasmid.

15. The method of claim 14, wherein the vector is an enterococcal shuttle vector.

16. The method of claim 13, wherein the vector contains a single copy of a *vanA* antisense molecule.

17. The method of claim 13, wherein the vector contains multiple copies of a *vanA* antisense molecule.

18. The method of claims 16 or 17, wherein the vector comprises a *VanR*-responsive promoter operatively coupled to the *vanA* antisense molecule.

19. The method of claim 1, wherein the anti-sense vancomycin resistance molecule is a *vanX* antisense molecule selected from the group consisting of:

an antisense molecule that hybridizes to the complete *vanX* gene sequence; and

an antisense molecule that hybridizes to a conserved region of the *vanX* gene sequence.

20. A method for reducing vancomycin resistance in a vancomycin-resistant organism comprising:

enhancing expression of a *vanH* promoter in the organism to an amount sufficient to reduce vancomycin resistance in the organism, wherein the *vanH* promoter is not operatively coupled to a vancomycin resistance gene of the organism.

21. The method of claim 20, wherein the *vanH* promoter is operatively coupled to an antisense vancomycin resistance molecule.

22. The method of claims 20 or 21, wherein the *vanH* promoter is contained on an enterococcus vector and enhancing expression comprises introducing into the organism an amount of the vector to express an amount of the *vanH* promoter sufficient to bind to phosphorylated *VanR* and thereby reduce vancomycin resistance in the organism.

23. The method of claim 20, further comprising co-administering into the organism an antisense vancomycin resistance molecule operatively coupled to a *vanH* promoter.

24. An isolated nucleic acid that hybridizes under stringent conditions to a nucleic acid molecule selected from the group consisting of SEQ ID NOs:1-13.

25. An isolated nucleic acid that hybridizes under stringent conditions to a nucleic acid molecule selected from the group consisting of SEQ ID NOs:5-13.

26. An isolated nucleic acid that hybridizes under stringent conditions to a nucleic acid molecule having a sequence selected from the group consisting of SEQ ID NOs:5-10.

27. A vector comprising an isolated nucleic acid molecule of any of claims 24, 25 or 26.

28. The vector of claim 27, further comprising a *vanH* promoter operatively coupled to the isolated nucleic acid molecule.

29. An isolated vancomycin resistant organism comprising a vector of claim 27 or 28.




Figure 1.

Figure 2.






Figure 3.




Figure 4.

SEQUENCE LISTING

<110> Beth Israel Deaconess Medical Center, Inc.
Inouye, Roger T.
Torres-Viera, Carlos
Moellering, Robert
Gold, Howard
Eliopoulos, George M.

<120> METHODS AND COMPOSITIONS FOR RESTORING ANTIBIOTIC SUSCEPTIBILITY IN GLYCOPEPTIDE-RESISTANT ENTEROCOCCUS

<130> B0662/7036WO/ERP/KA

<150> U.S. 60/149,313
<151> 1999-08-17

<160> 39

<170> FastSEQ for Windows Version 3.0

<210> 1
<211> 10851
<212> DNA
<213> Enterococcus faecium

<400> 1

ggggtagcgt caggaaaatg cggatttaca acgctaagcc tattttcctg acgaatccct 60
cgtttttaac aacgttaaga aagttttagt ggtcttaaag aatttaatga gactactttc 120
tctgagttaa aatggtattc tcctagtaaa ttaatatgtt cccaacctaa gggcgacata 180
tggtgtaaca aatcttcatt aaagctacct gtccgttttt tatattcaac tgctgttgtt 240
aggtggagag tattccaaat acttatagca ttgataatta tgtttaaagc actggctctt 300
tgcaattgat gctgtatggt gcgttctcta agctcacctt gttttccgaa gaaaatagct 360
cttgccaatc cattcatggc ttctccttta ttcaatcctc tttgtatttt tcttcttaat 420
gattcatccg atatataatt caaaataaag atcgtttttt ctattcggcc catctcacgt 480
aaggctgtag ctaagctgtt ttgtcttgaa taggaaccta gcttccccat aataagggat 540
gctgaaactg ttccctccct tatagaatga gctaatcgca aaacatcctc ataatttttct 600
ttaatgacct ttgtatttat ttgtccacgt aaaatggctt ctagttttgg atactcactt 660
gctttatcta tcgtaaataa ttttgagtcc gataaatccc ttattcttgg ggcaaattta 720
aatcctaata aatgagtcag tccgaatatt tggtcagtgt aaccggcagt gtctgtataa 780
tgttcctcta tgtttagatc cgtctcatga tgtaacaaac catccaaaac atgaatcgca 840
tctcttgaat tagtatgaat aatctttgtg tagtaagaag agaattgatc acttgtaaat 900
cggtagatgg tggctccttt tccagttcca taatgtggat ttgcatctgc atgtagtgat 960
gaaacaccta gctgcattct cataccatct gacgaagatg ttgtaccgtc gccccaatag 1020
aaaggcaatt gtaatttatg atgaaagttt actaatatgg cttgggcttt attcatggca 1080
tcttcataca tgcgccattg agatacattg gctagttgct tatatgtaag tccgggtgtg 1140
gcttcggcca tcttgctcaa gccaatattc attcccattc ctaaaagggc agccatgata 1200
atgattgttt cttccttatc tggttttcga ttattggaag catgagtgaa ttgctcatga 1260
aatcctgtta tatgggccac atccatgagt aaatcagtta attttattct tggtagcatc 1320
tgataaaggc ttgcactaaa tttttttgct tcttctggaa catctttttc taagcgtgca 1380
agtgatagct ttccttttttc aagagaaacc ccatctaact tattggaatt ggcagctaac 1440
cactttaacc tttcattaaa gctgctggtt ctctccgtta tataatcttc gaatgataaa 1500
ctaactgata atctcgtatt ccccttcgat tgattccatg tatcttccga aaacaaatat 1560
tcctcaaaat ccctatattg tctgctgcca acaatggaaa catctcctgc ccgaacatgc 1620
tcccgaagtt ctgttaaaac agccatttca tagtaatgac gattaattgt tgtaccatca 1680
tcctcgtata aatgtctttt ccatcgtttt gaaataaaat ccacaggtga gtcatcaggc 1740
acttttcgct ttccagattc gttcattcct cggataatct caacagcttg taaaagtggc 1800

tcatttgcct ttgtagaatg aaattccaat actcttaata gcgttggcgt atattttctt 1860
agtgaataaa accgtttttg cagtaagtct aaataatcat agtcggcagg acgtgcaagt 1920
tcctgagcct cttctactga agagacaaag gtattccatt caataaccga ttctaaaacc 1980
ttaaaaacgt ctaatttttc ctctcttgct ttaattaatg cttgtccgat gttcgtaaag 2040
tgtataactt tctcatttag ctttttaccg ttttgtttct ggatttcctc ttgagcctta 2100
cgacctttg ataacaaact aagtatttgc ctatcatgaa tttcaaacgc tttatccgtt 2160
agctcctgag taagttgtaa taaatagatg gttaatatcg aataacgttt attttcttga 2220
aagtcacgga atgcatacgg ctcgtatctt gagcctaagc gagacagctg caacaggcgg 2280
ttacggtgca aatgactaat ttgcactgtt tctaaatcca ttcctcgtat gtattcgagt 2340
cgttctatta tttttagaaa agtttcgggt gaaggatgac ccggtggctc ttttaaccaa 2400
cccaatatcg ttttattgga ttcggatgga tgctgcgagg taataatccc ttcaagcttt 2460
tctttttgct catttgttag agatttacta accgtattaa atagcttctt ttcagccatt 2520
gcccttgctt cccacaccat tctttcaagt gtagtgatag caggcagtat aattttgttt 2580
tttcttagaa aatctatgca ttcatgcagt agatgaatgg catcaccatt ttccaaagct 2640
aattgatgaa ggtacttaaa tgtcattcga tattcactca gggtaaaagt tacaaagtcg 2700
tattcacttc gaatttcttt caaatgatcc caaagtgtat tttccctttg aggataatga 2760
tcaagcgagg atggactaac accaatctgt ttcgatatat attgtatgac cgaatctggg 2820
atgcttttga tatgagtgta tggccaaccg ggataccgaa gaacagctaa ttgaacagca 2880
aatcctaaac ggttttcttc cctccttcgc ttattaacta tttctaaatc ccgtttggaa 2940
aaagtgaagt aggtccccag tatccattca tcttcaggga tttgcataaa agcctgtctc 3000
tgttccggtg taagcaattc tctacctctc gcaattttca ttcagtatca ttccatttct 3060
gtattttcaa tttattagtt caattatata tcaatagagt gtactctatt gatacaaatg 3120
tagtagactg ataaaatcat agttaagagc gtctcataag acttgtctca aaaatgaggt 3180
gatattttgc ggaaaatcgg ttatattcgt gtcagttcga ctaaccagaa tccttcaaga 3240
caatttcagc agttgaacga gatcggaatg gatattatat atgaagagaa agtttcagga 3300
gcaacaaagg atcgcgagca acttcaaaaa gtgttagacg atttacagga agatgacatc 3360
atttatgtta cagacttaac tcgaatcact cgtagtacac aagatctatt tgaattaatc 3420
gataacatac gagataaaaa ggcaagttta aaatcactaa aagatacatg gcttgattta 3480
tcagaagata atccatacag ccaattctta attactgtaa tggctggtgt taaccaatta 3540
gagcgagatc ttattcggat gagacaacgt gaagggattg aattggctaa gaaagaagga 3600
aagtttaaag gtcgattaaa gaagtatcat aaaaatcacg caggaatgaa ttatgcggta 3660
aagctatata aagaaggaaa tatgactgta aatcaaattt gtgaaattac taatgtatct 3720
agggcttcat tatacaggaa attatcagaa gtgaataatt agccattctg tattccgcta 3780
atgggcaata tttttaaaga agaaaaggaa actataaaat attaacagcc tcctagcgat 3840
gccgaaaagc cctttgataa aaaaagaatc atcatcttaa gaaattctta gtcatttatt 3900
atgtaaatgc ttataaattc ggccctataa tctgataaat tattaagggc aaacttatgt 3960
gaaagggtga taactatgag cgataaaata cttattgtgg atgatgaaca tgaaattgcc 4020
gatttggttg aattatactt aaaaaacgag aattatacgg ttttcaaata ctataccgcc 4080
aaagaagcat tggaatgtat agacaagtct gagattgacc ttgccatatt ggacatcatg 4140
cttcccggca caagcggcct tactatctgt caaaaaataa gggacaagca cacctatccg 4200
attatcatgc tgaccgggaa agatacagag gtagataaaa ttacagggtt aacaatcggc 4260
gcggatgatt atataacgaa gccctttcgc ccactggagt taattgctcg ggtaaaggcc 4320
cagttgcgcc gatacaaaaa attcagtgga gtaaaggagc agaacgaaaa tgttatcgtc 4380
cactccggcc ttgtcattaa tgttaacacc catgagtgtt atctgaacga gaagcagtta 4440
tcccttactc ccaccgagtt ttcaatactg cgaatcctct gtgaaaacaa ggggaatgtg 4500
gttagctccg agctgctatt tcatgagata tggggcgacg aatatttcag caagagcaac 4560
aacaccatca ccgtgcatat ccggcatttg cgcgaaaaaa tgaacgacac cattgataat 4620
ccgaaatata taaaaacggt atgggggttt ggttataaaa ttgaaaaata aaaaaaacga 4680
ctattccaaa ctagaacgaa aactttacat gtatatcgtt gcaattgttg tggtagcaat 4740
tgtattcgtg ttgtatattc gttcaatgat ccgagggaaa cttggggatt ggatcttaag 4800
tattttggaa aacaaatatg acttaaatca cctggacgcg atgaaattat atcaatattc 4860
catacggaac aatatagata tctttattta tgtggcgatt gtcattagta ttcttattct 4920
atgtcgcgtc atgctttcaa aattcgcaaa atactttgac gagataaata ccggcattga 4980
tgtacttatt cagaacgaag ataaacaaat tgagctttct gcggaaatgg atgttatgga 5040
acaaaagctc aacacattaa aacggactct ggaaaagcga gagcaggatg caaagctggc 5100
cgaacaaaga aaaaatgacg ttgttatgta cttggcgcac gatattaaaa cgccccttac 5160
atccattatc ggttatttga gcctgcttga cgaggctcca gacatgccgg tagatcaaaa 5220

ggcaaagtat gtgcatatca cgttggacaa agcgtatcga ctcgaacagc taatcgacga 5280
gttttttgag attacacggt ataacctaca aacgataacg ctaacaaaaa cgcacataga 5340
cctatactat atgctggtgc agatgaccga tgaattttat cctcagcttt ccgcacatgg 5400
aaaacaggcg gttattcacg cccccgagga tctgaccgtg tccggcgacc ctgataaact 5460
cgcgagagtc tttaacaaca ttttgaaaaa cgccgctgca tacagtgagg ataacagcat 5520
cattgacatt accgcgggcc tctccgggga tgtggtgtca atcgaattca agaacactgg 5580
aagcatccca aaagataagc tagctgccat atttgaaaag ttctataggc tggacaatgc 5640
tcgttcttcc gatacgggtg gcgcgggact tggattggcg attgcaaaag aaattattgt 5700
tcagcatgga gggcagattt acgcggaaag caatgataac tatacgacgt ttagggtaga 5760
gcttccagcg atgccagact tggttgataa aaggaggtcc taagagatgt atataatttt 5820
ttaggaaaat ctcaaggtta tctttacttt ttcttaggaa attaacaatt taatattaag 5880
aaacggctcg ttcttacacg gtagacttaa taccgtaaga acgagccgtt ttcgttcttc 5940
agagaaagat ttgacaagat taccattggc atccccgttt tatttggtgc ctttcacaga 6000
aagggttggt cttaattatg aataacatcg gcattactgt ttatggatgt gagcaggatg 6060
aggcagatgc attccatgct ctttcgcctc gctttggcgt tatggcaacg ataattaacg 6120
ccaacgtgtc ggaatccaac gccaaatccg cgcctttcaa tcaatgtatc agtgtgggac 6180
ataaatcaga gatttccgcc tctattcttc ttgcgctgaa gagagccggt gtgaaatata 6240
tttctacccg aagcatcggc tgcaatcata tagatacaac tgctgctaag agaatgggca 6300
tcactgtcga caatgtggcg tactcgccgg atagcgttgc cgattatact atgatgctaa 6360
ttcttatggc agtacgcaac gtaaaatcga ttgtgcgctc tgtggaaaaa catgatttca 6420
ggttggacag cgaccgtggc aaggtactca gcgacatgac agttggtgtg gtgggaacgg 6480
gccagatagg caaagcggtt attgagcggc tgcgaggatt tggatgtaaa gtgttggctt 6540
atagtcgcag ccgaagtata gaggtaaact atgtaccgtt tgatgagttg ctgcaaaata 6600
gcgatatcgt tacgcttcat gtgccgctca atacggatac gcactatatt atcagccacg 6660
aacaaataca gagaatgaag caaggagcat ttcttatcaa tactgggcgc ggtccacttg 6720
tagataccta tgagttggtt aaagcattag aaaacgggaa actgggcggt gccgcattgg 6780
atgtattgga aggagaggaa gagtttttct actctgattg cacccaaaaa ccaattgata 6840
atcaattttt acttaaac t caaagaatgc ctaacgtgat aatcacaccg catacggcct 6900
attataccga gcaagcgttg cgtgataccg ttgaaaaaac cattaaaaac tgtttggatt 6960
ttgaaaggag acaggagcat gaatagaata aaagttgcaa tactgtttgg gggttgctca 7020
gaggagcatg acgtatcggt aaaatctgca atagagatag ccgctaacat taataaagaa 7080
aaatacgagc cgttatacat tggaattacg aaatctggtg tatggaaaat gtgcgaaaaa 7140
ccttgcgcgg aatgggaaaa cgacaattgc tattcagctg tactctcgcc ggataaaaaa 7200
atgcacggat tacttgttaa aaagaaccat gaatatgaaa tcaaccatgt tgatgtagca 7260
ttttcagctt tgcatggcaa gtcaggtgaa gatggatcca tacaaggtct gtttgaattg 7320
tccggtatcc cttttgtagg ctgcgatatt caaagctcag caatttgtat ggacaaatcg 7380
ttgacataca tcgttgcgaa aaatgctggg atagctactc ccgccttttg ggttattaat 7440
aaagatgata ggccggtggc agctacgttt acctatcctg tttttgttaa gccggcgcgt 7500
tcaggctcat ccttcggtgt gaaaaaagtc aatagcgcgg acgaattgga ctacgcaatt 7560
gaatcggcaa gacaatatga cagcaaaatc ttaattgagc aggctgtttc gggctgtgag 7620
gtcggttgtg cggtattggg aaacagtgcc gcgttagttg ttggcgaggt ggaccaaatc 7680
aggctgcagt acggaatctt tcgtattcat caggaagtcg agccggaaaa aggctctgaa 7740
aacgcagtta taaccgttcc cgcagacctt tcagcagagg agcgaggacg gatacaggaa 7800
acggcaaaaa aaatatataa agcgctcggc tgtagaggtc tagcccgtgt ggatatgttt 7860
ttacaagata acggccgcat tgtactgaac gaagtcaata ctctgcccgg tttcacgtca 7920
tacagtcgtt atccccgtat gatggccgct gcaggtattg cacttcccga actgattgac 7980
cgcttgatcg tattagcgtt aaaggggtga taagcatgga aataggattt acttttttag 8040
atgaaatagt acacggtgtt cgttgggacg ctaaatatgc cacttgggat aatttcaccg 8100
gaaaaccggt tgacggttat gaagtaaatc gcattgtagg gacatacgag ttggctgaat 8160
cgcttttgaa ggcaaaagaa ctggctgcta cccaagggta cggattgctt ctatgggacg 8220
gttaccgtcc taagcgtgct gtaaactgtt ttatgcaatg ggctgcacag ccggaaaata 8280
acctgacaaa ggaaagttat tatcccaata ttgaccgaac tgagatgatt tcaaaaggat 8340
acgtggcttc aaaatcaagc catagccgcg gcagtgccat tgatcttacg ctttatcgat 8400
tagacacggg tgagcttgta ccaatgggga gccgatttga ttttatggat gaacgctctc 8460
atcatgcggc aaatggaata tcatgcaatg aagcgcaaaa tcgcagacgt ttgcgctcca 8520
tcatggaaaa cagtgggttt gaagcatata gcctcgaatg gtggcactat gtattaagag 8580
acgaaccata ccccaatagc tattttgatt tccccgttaa ataaactttt aaccgttgca 8640

cggacaaact atataagcta actctttcgg caggaaaccc gacgtatgta actggttctt 8700
agggaattta tatatagtag atagtattga agatgtaagg cagagcgata ttgcggtcat 8760
tatctgcgtg cgctgcggca agatagcctg ataataagac tgatcgcata gaggggtggt 8820
atttcacacc gcccattgtc aacaggcagt tcagcctcgt taaattcagc atgggtatca 8880
cttatgaaaa ttcatctaca ttggtgataa tagtaaatcc agtagggcga aataattgac 8940
tgtaatttac ggggcaaaac ggcacaatct caaacgagat tgtgccgttt aaggggaaga 9000
ttctagaaat atttcatact tccaactata tagttaagga ggagactgaa aatgaagaag 9060
ttgtttttt tattgttatt gttattctta atatacttag gttatgacta cgttaatgaa 9120
gcactgtttt ctcaggaaaa agtcgaattt caaaattatg atcaaaatcc caaagaacat 9180
ttagaaaata gtgggacttc tgaaaatacc caagagaaaa caattacaga agaacaggtt 9240
tatcaaggaa atctgctatt aatcaatagt aaatatcctg ttcgccaaga aagtgtgaag 9300
tcagatatcg tgaatttatc taaacatgac gaattaataa atggatacgg gttgcttgat 9360
agtaatattt atatgtcaaa agaaatagca caaaaatttt cagagatggt caatgatgct 9420
gtaaagggtg gcgttagtca ttttattatt aatagtggct atcgagactt tgatgagcaa 9480
agtgtgcttt accaagaaat gggggctgag tatgccttac cagcaggtta tagtgagcat 9540
aattcaggtt tatcactaga tgtaggatca agcttgacga aaatggaacg agcccctgaa 9600
ggaaagtgga tagaagaaaa tgcttggaaa tacgggttca ttttacgtta tccagaggac 9660
aaaacagagt taacaggaat tcaatatgaa ccatggcata ttcgctatgt tggtttacca 9720
catagtgcga ttatgaaaga aaagaatttc gttctcgagg aatatatgga ttacctaaaa 9780
gaagaaaaaa ccatttctgt tagtgtaaat ggggaaaaat atgagatctt ttattatcct 9840
gttactaaaa ataccaccat tcatgtgccg actaatcttc gttatgagat atcaggaaac 9900
aatatagacg gtgtaattgt gacagtgttt cccggatcaa cacatactaa ttcaaggagg 9960
taaggatggc ggaatgaaac caacgaaatt aatgaacagc attattgtac tagcactttt 10020
ggggtaacgt tagcttttta atttaaaacc cacgttaact aggacattgc tatactaatg 10080
atacaactta aacaaaagaa ttagaggaaa ttatattggg aaaaatatta tctagaggat 10140
tgctagcttt atatttagtg acactaatct ggttagtgtt attcaaatta caatacaata 10200
ttttatcagt atttaattat catcaaagaa gtcttaactt gactccattt actgctactg 10260
ggaatttcag agagatgata gataatgtta taatctttat tccatttggc ttgcttttga 10320
atgtcaattt taaagaaatc ggatttttac ctaagtttgc ttttgtactg gttttaagtc 10380
ttacttttga aataattcaa tttatcttcg ctattggagc gacagacata acagatgtaa 10440
ttacaaatac tgttggaggc tttcttggac tgaaattata tggtttaagc aataagcata 10500
tgaatcaaaa aaaattagac agagttatta tttttgtagg tatacttttg ctcgtattat 10560
tgctcgttta ccgtacccat ttaagaataa attacgtgta agatgtctaa atcaagcaat 10620
ctgatctttc atacacataa agatattgaa tgaattggat tagatggaaa acgggatgtg 10680
gggaaactcg cccgtaggtg tgaagtgagg ggaaaaccgg tgataaagta aaaagcttac 10740
ctaacactat agtaacaaag aaagcccaat tatcaatttt agtgctgagg aattggtctc 10800
tttaataaat ttccttaacg ttgtaaatcc gcattttcct gacggtaccc c 10851

<210> 2
<211> 7160
<212> DNA
<213> Enterococcus faecalis

<400> 2
tttaaacggt atatttcgga agaactgtgg aaacggctta tctctgtaaa atggggcatt 60
acagggcgtt gggtacaaaa gctctgcgat ggacgattaa aatccgaaaa gaaatcgctt 120
tgaaactaca gggaaactac agactgttat gttatcttct taaatggagg gatttttatg 180
tcgatacgaa ttctacttgt cgaggatgat gatcatatct gcaatacagt aagggcgttt 240
ttggctgaag caagatatga ggtggatgcc tgcacagatg gaaacgaagc acacaccaag 300
ttctatgaaa acacctatca actggttatt cttgatatta tgctgcccgg tatgaatggg 360
catgaacttc tacgtgaatt tcgggcgcaa aatgataccc ccattctgat gatgacagcc 420
ctgtcggatg acgaaaacca aatccgggcg tttgatgcag aggcagacga ctatgtaaca 480
aagccattca agatgcggat tttactaaag cgggtggaag ccctgttacg gcgcagcggt 540
gcgctggcaa aggaatttcg tgtgggcagg ctgacacttc tgccggagga ttttagggta 600
ctttgtgacg gtacggagct gcccctgaca cgaaaagaat ttgaaatcct tttgctgctg 660

gtgcagaaca aaggcagaac cttaacccat gaaatcattt tgtcccgcat atggggatat 720
gactttgacg gtgatggcag cacagtccac actcatatca aaaatctgcg ggcgaagctg 780
ccggaaaata tcatcaaaac catccgcggt gtaggttacc gattggagga atcattataa 840
tggaaagaaa agggattttc attaaggttt tttcctatac gatcattgtc ctgttactgc 900
ttgtcggtgt aacggcaaca ctgtttgcac agcaatttgt gtcttatttc agagcgatgg 960
aagcacagca aacagtaaaa tcctatcagc cattggtgga actgattcag aatagcgata 1020
ggcttgatat gcaagaggtg gcagggctgt ttcactacaa taaccaatcc tttgagtttt 1080
atattgaaga taaagaggga agcgtactct atgccacacc gaatgccgat acatcaaata 1140
gtgttaggcc cgactttctt tatgtggtac atagagatga taatatttcg attgttgctc 1200
aaagcaaggc aggtgtggga ttgctttatc aagggctgac aattcgggga attgttatga 1260
ttgcgataat ggttgtattc agccttttat gcgcgtatat ctttgcgcgg caaatgacaa 1320
cgccgatcaa agccttagcg gacagtgcga ataaaatggc aaacctgaaa gaagtaccgc 1380
cgccgctgga gcgaaaggat gagcttggcg cactggctca cgacatgcat tccatgtata 1440
tcaggctgaa agaaaccatc gcaaggctgg aggatgaaat cgcaagggaa catgagttgg 1500
aggaaacaca gcgatatttc tttgcggcag cctctcatga gttaaaaacg cccatcgcgg 1560
ctgtaagcgt tctgttggag ggaatgcttg aaaatatcgg tgactacaaa gaccattcta 1620
agtatctgcg cgaatgcatc aaaatgatgg acaggcaggg caaaaccatt tccgaaatac 1680
tggagcttgt cagcctgaac gatgggagaa tcgtacccat agccgaaccg ctggacatag 1740
ggcgcacggt tgccgagctg ctacccgatt ttcaaacctt ggcagaggca aacaaccagc 1800
ggttcgtcac agatattcca gccggacaaa ttgtcctgtc cgatccgaag ctgatccaaa 1860
aggcgctatc caatgtcata ttgaatgcgg ttcagaacac gccccaggga ggtgaggtac 1920
ggatatggag tgagcctggg gctgaaaaat accgtctttc cgttttgaac atgggcgttc 1980
acattgatga tactgcactt tcaaagctgt tcatcccatt ctatcgcatt gatcaggcgc 2040
gaagcagaaa aagtgggcga agcggtttgg ggcttgccat cgtacaaaaa acgctggatg 2100
ccatgagcct ccaatatgcg ctggaaaaca cctcagatgg cgttttgttc tggctggatt 2160
taccgcccac atcaacacta taaatattta aaacttaaat gattttgacc gacaggtata 2220
accctgccgg tctttttgtt tttcgccgct acaggaaaac tacagattga ctacagggaa 2280
agtacagata cgcttgccat attaacaatc gtaccagcca caaatcgtag ttttattgca 2340
aaggaggcat tcaatcaaat ggaaaaaagc aactatcatt ccaatgtgaa tcatcacaaa 2400
cggcatatga aacaatctgg ggaaaaacgg gcttttctat gggcgttcat tatctcgttc 2460
acagtctgca cgctgttttt ggggtggaga ttggtttccg tattggaggc aacacagcta 2520
ccgcccatcc ctgcaactca tacaggcagc gggactggtg tagcggagaa tccagaggaa 2580
aacactcttg ccaccgccaa agaacaggga gatgaacagg aatggagcct gattttagtg 2640
aacaggcaga accccatccc cgcccagtac gatgtggaac ttgagcagct gtcaaatggt 2700
gagcggatag acattcggat ttctccctac ctccaggatt tgtttgatgc cgcaagagct 2760
gatggagttt acccgattgt cgcatccgga taccggacaa cagaaaaaca gcaagaaatc 2820
atggatgaaa aagtcgccga atacaaggcg aaaggctaca cctctgcaca ggctaaagcg 2880
gaagcagaaa cttgggtggc cgtgccggga acaagcgagc atcagcttgg tcttgctgtg 2940
gatatcaatg cggatggaat tcattcaacc ggcaacgagg tttacagatg gctggatgaa 3000
aacagctatc gctttggttt tattcgccgc tacccgccag acaagacaga gataaccggt 3060
gtgagcaacg agccgtggca ttaccgatat gtcggcatcg aagctgccac aaagatatac 3120
caccaagggc tttgccttga ggaatattta aacacagaaa aatgagaaaa ggatataatg 3180
ctatgaacag aaaaagattg acacagcgct tcccgttcct gcttccaatg agacaagcgc 3240
agagaaaaat atgcttttat gcgggaatga gatttgacgg ctgttgctat gcacagacga 3300
taggagaaaa aacgcttccc tatttgctct ttgaaacgga ttgtgcgtta tacaaccaca 3360
ataccggatt tgacatgata taccaagaaa acaaggtgtt caacttaaag ctggcggcaa 3420
agaccttaaa cggcctattg ataaaaccgg gggaaacctt ttctttctgg cggctggtac 3480
gccatgcgga caaagatacc ccctataaag acggccttac ggtggccaat ggtaagctca 3540
ccaccatgtc gggcggcggt atgtgccaga tgagcaattt actattttgg gtgttcctgc 3600
atacgccatt gacaattatc cagcgcagcg gtcacgtagt aaaggagttt ccagagccaa 3660
acagtgacga gatcaaaggg gtggatgcaa ccatctcaga gggctggatt gatttaaaag 3720
tgcgaaacga taccgactgc acctaccaaa tatgggtgac cctagatgat gagaaaatca 3780
tcggtcaggt gttcgccgac aaacagcctc aagcattata caaaattgca aacggcagta 3840
ttcagtatgt ccgtgaaagt ggcgggattt atgaatatgc caaggttgaa cggatgcaag 3900
ttgccttagg taccggggaa ataatagatt gcaagctgct ttatacaaac aaatgcaaaa 3960
tctgctatcc cctcccggaa agtgtggata ttcaggaggc gaaccaatga gaaaaagtat 4020
gggcattact gtttttggat gcgagcagga tgaggcaaat gctttccgca ccttatcacc 4080

agattttcat attatcccta cgctgatcag tgatgcgata tcggcagaca acgcaaaatt 4140
ggccgctggc aatcaatgca ttagcgtagg ccataagtcc gaggtttccg aggcgacaat 4200
tcttgcgctg agaaaggtcg gggtaaaata catttctacc cgcagcatcg gctgcaatca 4260
cattgatacg actgccgccg agagaatggg gatctcggtt ggcacagttg cgtattcgcc 4320
ggacagcgtt gcggattatg ctttgatgct gatgctgatg gccatacggg gtgcaaagtc 4380
caccatacac gccgtggcgc aacaaaattt cagactggat tgtgtccggg ggaaagagct 4440
gcgggatatg actgtgggag ttattggaac cggccatata gggcaagcgg tcgtcaaaag 4500
gctgcgggga tttggatgcc gtgtgctagc ctatgataac agccgaaaaa ttgaggcaga 4560
ttatgtccag cttgatgagc ttctaaaaaa cagcgatatt gttacgctcc atgtgccgct 4620
ttgtgcggat acccgccatc tgatcggcca gagcgaaatc ggagagatga agcaaggcgc 4680
atttttaatc aacactgggc gcggggcgct tgtcgatacc gggtcgctgg tggaggcact 4740
gggaagcgga aagctgggcg gtgcggcact ggatgtgttg gagggcgagg atcagtttgt 4800
ttataccgac tgctcgcaga aagtgcttga ccatcccttt ttgtcgcagc tcctaaggat 4860
gccaaatgtg atcatcacac cccatacggc gtactacacc gagcgtgtgc tgcgagatac 4920
cacagaaaaa acaatcagga attgtcttaa ctttgaaagg agtttacagc atgaataaaa 4980
taaaagtcgc aattatcttc ggcggttgct cggaggaaca tgatgtgtcg gtaaaatccg 5040
caatagaaat tgctgcgaac attaatactg aaaaattcga tccgcactac atcggaatta 5100
caaaaaacgg cgtatggaag ctatgcaaga agccatgtac ggaatgggaa gccgatagtc 5160
tccccgccat attctccccg gataggaaaa cgcatggtct gcttgtcatg aaagaaagag 5220
aatacgaaac tcggcgtatt gacgtggctt tcccggtttt gcatggcaaa tgcggggagg 5280
atggtgcgat acagggtctg tttgaattgt ctggtatccc ctatgtaggc tgcgatattc 5340
aaagctccgc agcttgcatg gacaaatcac tggcctacat tcttacaaaa aatgcgggca 5400
tcgccgtccc cgaatttcaa atgattgaaa aaggtgacaa accggaggcg aggacgctta 5460
cctaccctgt ctttgtgaag ccggcacggt caggttcgtc ctttggcgta accaaagtaa 5520
acagtacgga agaactaaac gctgcgatag aagcagcagg acaatatgat ggaaaaatct 5580
taattgagca agcgatttcg ggctgtgagg tcggctgcgc ggtcatggga aacgaggatg 5640
atttgattgt cggcgaagtg gatcaaatcc ggttgagcca cggtatcttc cgcatccatc 5700
aggaaaacga gccggaaaaa ggctcagaga atgcgatgat tatcgttcca gcagacattc 5760
cggtcgagga acgaaatcgg gtgcaagaaa cggcaaagaa agtatatcgg gtgcttggat 5820
gcagagggct tgctcgtgtt gatctttttt tgcaggagga tggcggcatc gttctaaacg 5880
aggtcaatac cctgcccggt tttacatcgt acagccgcta tccacgcatg gcggctgccg 5940
caggaatcac gcttcccgca ctaattgaca gcctgattac attggcgata gagaggtgac 6000
ccgtatggaa aatggttttt tgtttttaga tgaaatgttg catggtgttc gttgggatgc 6060
caagtacgct acatgggata acttcacggg aaaaccagtg gatgggtatg aggtgaatcg 6120
catcatcggc acaaaggccg tggcgcttgc tctgcgcgaa gcacaaatcc atgcggcacg 6180
ccttggctac ggcttgcttt tatgggatgg atatcggcca aaatctgcgg tggactgttt 6240
cctgcgttgg gcggcgcagc cggaggacaa cctcacaaaa gaaaaatatt accccaatat 6300
tgagcgagcc gagttgatta caaagggcta tgtggcctca caatccagcc atagccgtgg 6360
aagcacaatt gatcttacgc tctaccactt ggatacaggg gaacttgttt caatgggaag 6420
caacttcgat tttatggacg aacggtcgca ccatacagca aaagggatag ggaatgcaga 6480
ggcacaaaat cgaagatgct tgcgtaaaat catggaaagc agcggatttc agtcctatcg 6540
ctttgaatgg tggcactata agttgattga tgagccatac cccgatacct attttaattt 6600
tgctgtttca taatgaaagt atttgatttt ctaattatgt ataagttggc tacaaattac 6660
ttagtatttc atcagaccaa ttactctctt gtttacagaa aaattctgcg ctgatggaat 6720
ctgctttatt atgcgggcga aaaatgaaat tgaccatatt ttttcagaac tttactctgt 6780
accgaattgc ctgcaaaagc cttattttaa gctgaaagtt caggaattgc ttttgttttt 6840
gtgtatgccc ctcgtgattt gtacacctat cttaattggc tttgcaattc tcattccgta 6900
tctctgcttt aagaatttgg aaaaacgaag cattgtgaat cggctgcggg cagagcaaaa 6960
agagaaccag cagaaacaag tcgttcttgc tctgctgatt cactcggaac tgtttgattc 7020
gggttttcgt tgaaggtcaa gtagctgctc tgtcaggaag tccagtgtgt tcagcagaat 7080
ctgctgattg tcacggttgc atgactgaaa ttttcccatg aaacgctgga gttcttcatc 7140
ctcaatagag tttgaagctt 7160

<210> 3
<211> 1086

<212> DNA
<213> Enterococcus casseliflavus

<400> 3

gtaagaatcg gaaaagcgga aggaagaaaa acatgaaaaa aatcgccatt atttttggag 60
gcaattcacc ggaatacacc gtttctttag cttcagcaac tagcgcaatc gaagcactcc 120
aatcatctcc ctatgactac gacctctctt tgatcgggat cgccccagat gctatggatt 180
ggtacttgta tacaggagaa ctggaaaaca tccgacaaga cacgtggttg ttggatacga 240
aacataaaca gaaaatacag ccgctattcg aaggaaacgg cttttggcta agtgaagagc 300
agcaaacgtt ggtacctgat gttttatttc ccattatgca tggcaaatac ggggaagatg 360
gcagtatcca aggattgttt gaattgatga agctgcctta tgtaggctgc ggggtggcag 420
gttctgcctt atgtatgaac aaatggctgc tgcatcaagc tgcagcagcc attggcgtac 480
aaagtgctcc tacgattctc ttgacaaatc aagccaacca gcaagaacaa atcgaagctt 540
ttatccagac ccatggcttc ccagttttct ttaagcctaa tgaagcgggc tcctcaaaag 600
ggatcactaa agtcacctgc gttgaagaaa tcgcttctgc cttaaaagaa gcctttactt 660
attgttccgc agtgctccta caaaaaaata ttgccggtgt tgagatcggt tgcggtattt 720
tgggcaacga ctctttgact gtcggtgctt gtgacgccat ttcattagta gacggctttt 780
tcgattttga agaaaagtac cagctgatca gcgccaaaat caccgtccct gcgccattgc 840
ctgaaacgat tgaaaccaag gtcaaagaac aagctcagct gctctatcgt agtcttggtc 900
ttaaaggtct tgctcgcatc gacttttttg tcacggagcg aggagaacta tacttgaatg 960
aaatcaatac tatgccgggc tttacgagtc actcccgcta tcctgccatg atggcagcgg 1020
tcggcttatc ctatcaagaa ctactacaaa aactgcttgt cttagcaaag gaggaagtca 1080
aatgag 1086

<210> 4
<211> 5781
<212> DNA
<213> Enterococcus faecium

<400> 4

attaatctgc attgttgttt catatcgatt ttgacacata ataaagacag attatcgcaa 60
tgtaaggagt aatgcaatga atgaaaaaat cttagtggtt gatgatgaaa aagaattggc 120
cgacttagtt gaagtatatc tgaaaaacga tggatatacc gtttataaat tttataatgg 180
caaggatgca ctaaagtgta ttgaatccgt ggaactggat ttagccatat tggatatcat 240
gcttccggat gtagacgggt ttcagatctg ccagaaaatc cgggaaaagt tttacttccc 300
tgttatcatg ctgacagcaa aagtggagga cggggataaa atcatgggac tgtccgtggc 360
ggatgattat attacaaagc cgtttaaccc gctggaagtg gttgcgagag taaaggcgca 420
gctgcggcag tacatgcggt acaagcagcc cagcttaaag caggaggctg aatgcacaga 480
atacgatatc agagggatga caatcagcaa gagcagccat aagtgtatcc tgtttggaaa 540
ggagattcag ctgacgccaa cggagttttc gattctttgg tatctgtgcg agcgtcaggg 600
tacggttgtt tctacggagg aattatttga ggcagtatgg ggtgaacggt tttttgacag 660
caataatact gtgatggcgc atatcgggcg gctccgggag aaaatgaagg aaccgtcaag 720
aaatccgaaa tttataaaaa ctgtgtgggg agtgggatat accattgaaa aatagaaata 780
aaaccagtca tgaagatgac tatttacttt ttaaaaacag attgtccgtt aaaatactgc 840
ttatgatggt atattccatt ctgattattg cgggtgttta tctgtttatc ttaaaagata 900
attttgcaaa tgtcgtggta gccattttag acagctttat ctatcatgat cgggatgagg 960
cggtggctgt ttatctgaga acctttaagg cgtctgagat atggcttttc ctgatagcgg 1020
ttatgggcgt gttttttatg atcttccgcc gttatctgga cagtatttca aaatatttta 1080
aggagatcaa ccgggggatc gatactttgg tgaatgagga tgccaacgat attgggctgc 1140
ctccggagtt ggcttcgacc gaaagaaaaa tcaattccat acggcatacc ctgacgaaac 1200
ggaaaacgga cgctgagctt gcagagcaaa ggaaaaacga tcttgtcatg tatctggccc 1260
atgacctgaa gaccccgctt ccatcggtca taggatattt gaacctgtta agggatgaga 1320
atcagatttc cgaggaactt agggaaaaat atttgtccat atcattggat aaggctgagc 1380
gtctggaaga actgattaat gagtttttg aaattacgag gtttaatctt tcaaacatca 1440
cgcttgtgta cagcaaaatc aatctgacga tgatgctgga acagctgggg tatgagttta 1500
agccgatgct ggccgggaaa aatctgaaat gtgaatttga tgttcagcca gacatgatgc 1560
tgtcctgcga tgccaacaag ctgcagcggg tcttcgataa tgtgctgaga aatgccgtca 1620

gctactgcta tgagaatacc accattcggg tgaaagccag gcagaccgaa gaccatgtac 1680
tcatcaaaat cataaacgaa ggggatacga ttcctgggga gagattggaa agaatctttg 1740
agcagtttta ccgcctggat gtatctcgaa gctcaagtac cggcggggcc ggtctggggc 1800
ttgccattgc aaaagagatt gtggaactgc accatggaca gatcactgcc cacagcgaaa 1860
atggtatcac cagttttgag gttacattgc ccgtcgtagg aaaatcgtaa gaaattccga 1920
gataaaccgt gtgttatcca taaaagaacg cgaaaacata aatcgctcta ttctggtatg 1980
ctttatatca ggaggggcga ttttttgct ttcagaaagg agttcagggt aatgatggaa 2040
tatcaaaaca ataatggaaa ctatgacaaa aggaatcgta gaaaagccaa aaaaagaaaa 2100
ttgctttttt acagggctgc atgtgtcaca ctttgtttgc tcattgtttc tgtaatcttt 2160
ggagttgtgc atttttagg ggagagtaaa gatcccggcc ttttatccaa agaaaacaca 2220
aaaacagaca agaactattc gtggcttacc gacgatcaga atgaggcagt accctcagtt 2280
ccagagccag ccatatccga ccaggctaac aaaatttcgg taaatatcac agcggcaaac 2340
gccattgtaa tgaataaaga cacaaatgag gtattgtacc agaaaaaaag cacagccaaa 2400
attgcgccgg ccagcactgc taagatgatt atggctttga cagcacttga ctattgttcc 2460
ccggaggatg aaatgaaagt aggtgcggag attggaatga ttcaaagcga ttcgtcaacc 2520
gcatggctta tgaagggtga tacactgact gtcagacagc tcctgattgc ccttatgctt 2580
ccgtccggca atgatgcagc ctataccctt gcagtcaata ccggaaaggc tattgcaggt 2640
gataacagcc tgaccagtca gcaagcgatt gaagtattca tggataaggt aaatgaaaaa 2700
gccgtggccc ttggcgccac aaactcgaaa tttgtagctc cggatggata tgatgccgaa 2760
gggcagtata ctacagctta tgaccttgct atcattgcaa aagcatgttt ggacaatcct 2820
atcatttcgg agattgtagc gagttattca tcctatgaaa aatggtcaaa cggaagagag 2880
gtcacttaca acaattccaa tgagcttctc gatccgaaca gtccctatta ccgtccggag 2940
gttatcggtt tgaaaacagg aaccagcagt cttggcggcg catgtattgt ttctgcagcg 3000
gtgatggacg gagaaaccta tatctgtgta gttatgggtt ctacaaagga aagcaggttt 3060
caggacagcg ttgatatttt agataaaatc aaagcccagt aacgagataa ggaggaaatg 3120
aatggagaaa ataatagaca taactgtttt tggctgcgag ccagacgaaa tggaggtttt 3180
tcaaaagatt tcttatgagc ttggtgttac agccacactc ataaaagatt ctatatcaga 3240
aagcaatgct ggattagcta atggatgccg gtgtgtaagc gtaagccata aagcggagct 3300
atcagaaccg attcttcttg cgctaaaaaa tgcaggggta aaatatatca gtacccggag 3360
cattggtttt aaccatattg atatacaggc ggctgggtta ctgggtatgg ttgttggcac 3420
agtagaatac tcgccgggaa gtgtggccga ttataccgtc atgctgatgc ttatgctgat 3480
gcgtggcaca aagtcgattc tgcgtgaaac ccagaggcag aattattgcc tgaatgacct 3540
gcgcggaaaa gaactgcggg atatgaccgt gggtgtgtta ggaactgggc gaatcggaca 3600
ggcagtcatg gagcgcctgg agggattcgg ttgtaaggta ttggcgtatg accgaaatca 3660
aaaagcagga gcagactatg tttcgtttca tgaactgctg aaaaaaagtg acattgttac 3720
actgcatatc ccgttggcgg aggatacccg ccatatgatt ggctatgaag agctggaaat 3780
gatgaaggaa gaggcgcttc tgatcaatac agggcggggc gctttagtgg ataccgcagc 3840
attggtagaa gcattaaaag gacagaaaat cggcggcgcc ctggatgttt tggaaggcga 3900
agaaggtatc ttttaccatg actgcaccca aagaagaata gaacatcctt tcctgtcggt 3960
cctgcaggga atgccgaatg tcattgttac gccgcacaca gcctatcata cggaacgggt 4020
gttggttgac acggtcagaa atactattag aaattgtttg aattttgaaa ggagtctggg 4080
aaatgtttag aattaaagtt gcagttctgt ttgggggctg ttcagaggaa cataatgttt 4140
cgataaaatc tgcgatggag attgccgcaa acatagatac aaaaaaatat cagccttatt 4200
atattggaat cacaaaatcc ggcgtttgga aaatgtgtga aaaaccttgt ttggagtggg 4260
aacaatatgc gggggatccg gttgtttttt cgccggacag aagtacgcat ggtctgctga 4320
tacaaaaaga caaagggtat gaaatccagc ctgtggatgt ggtgtttccg atgattcatg 4380
gcaagtttgg ggaggatggc tccatacaag gcttgcttga attgtcaggc attccgtatg 4440
tgggatgcga tattcaaagc tccgtgatct gcatggataa ggcgcttgca tataccgttg 4500
tgaaaaatgc gggtatcact gtgcctgggt tccggatcct tcaggagggg gatcgcctgg 4560
aaacggagga tttcgtatat cccgtttttg taaagcctgc ccgttccggc tcatcctttg 4620
gcgtaaacaa ggtatgcaag gcagaagaac tgcaggcagc aatcgaagaa gcaagaaaat 4680
atgacagcaa gattttgatt gaagaggccg ttaccgggag tgaggtaggc tgcgccatac 4740
tgggaaacgg aaatgatctc atggctggcg aggtggatca gattgagctg agacacggct 4800
tttttaagat tcatcaggaa gcacagccgg agaagggatc tgaaaatgca gtcatccgag 4860
ttccagccgc cttaccggat gaggtaagag aacagattca ggaaacggca atgaagattt 4920
accggatact tggctgcaga ggattggccc gcattgacct gtttttgcgg gaggacggtt 4980
gcattgtgct gaatgaagtg aataccatgc caggttttac ttcctacagc cgctatcccc 5040

gcatgatgac agcagccggt tttacgcttt ctgaaatact ggatcgcttg attgaacttt 5100
cacttaggag gtaactgtca tgaaaaagaa ctttgccttt ttagatgaaa tgattcccgg 5160
gatccgatgg gatgccaaat atgccacctg ggacaatttc accgggaaac cggtagacgg 5220
atacatggta aaccgtgtta tgggaacgaa ggagctggga gttgctttgc gtaaggctca 5280
gaagatggcg gagaagctag gatatggttt gctcttatgg gacggctatc gcccccagtg 5340
cgcagtgaat tgttttctga attgggcttc ccaaccggaa gacaatctga cgaaaaagcg 5400
ttactatcca aatatcaaaa ggaatgagat ggttgcgaag gggtatgtgg cctcacaatc 5460
cagccacagc cgtggaagta cggttgacct tacaattttt catttgaata gcggtatgct 5520
tgttcctatg ggtggagatt ttgactttat ggatgaacgg tcacaccatg ccgcaagcgg 5580
tctgagcgaa gaagaatcaa aaaaccggca gtgcttgcgt tatatcatgg agagtagcgg 5640
atttgaagcc tatcgttatg aatggtggca ttacgtcttg gcggacgagc catacccgga 5700
tacatatttt gatttttgca ttgcctagtg agagcctgaa gaaatgaaaa atgtaagatt 5760
ataaggacaa gcggcatgag g 5781

<210> 5
<211> 27
<212> DNA
<213> Enterococcus faecium

<400> 5
ggtggcgcgg gacttggatg gcgattg 27

<210> 6
<211> 30
<212> DNA
<213> Enterococcus faecium

<400> 6
ggcgcggatg attatataac gaagcccttt 30

<210> 7
<211> 18
<212> DNA
<213> Enterococcus faecium

<400> 7
cgagccggaa aaaggctc 18

<210> 8
<211> 20
<212> DNA
<213> Enterococcus faecium

<400> 8
ggctgcgata ttcaaagctc 20

<210> 9
<211> 27
<212> DNA
<213> Enterococcus faecium

<400> 9
attactgttt atggatgtga gcaggat 27

<210> 10

<211> 26
<212> DNA
<213> Enterococcus faecium

<400> 10
gtggcttcaa aatcaagcca tagccg 26

<210> 11
<211> 18
<212> DNA
<213> Enterococcus casseliflavus

<400> 11
cgagccggaa aaaggctc 18

<210> 12
<211> 20
<212> DNA
<213> Enterococcus casseliflavus

<400> 12
ggctgcgata ttcaaagctc 20

<210> 13
<211> 20
<212> DNA
<213> Enterococcus faecium

<400> 13
ggctgcgata ttcaaagctc 20

<210> 14
<211> 30
<212> DNA
<213> Enterococcus faecium

<400> 14
cuacuacuac uacgaattca agaacactgg 30

<210> 15
<211> 36
<212> DNA
<213> Enterococcus faecium

<400> 15
caucaucauc auccaaccct ttctgtgaaa ggcacc 36

<210> 16
<211> 38
<212> DNA
<213> Enterococcus faecium

<400> 16
cuacuacuac uactcgaggc ttatcacccc tttaacgc 38

<210> 17
<211> 32

<212> DNA
<213> Enterococcus faecium

<400> 17
caucaucauc auggagacag gagcatgaat ag 32

<210> 18
<211> 696
<212> DNA
<213> Enterococcus faecium

<400> 18
atgagcgata aaatacttat tgtggatgat gaacatgaaa ttgccgattt ggttgaatta 60
tacttaaaaa acgagaatta tacggttttc aaatactata ccgccaaaga agcattggaa 120
tgtatagaca agtctgagat tgaccttgcc atattggaca tcatgcttcc cggcacaagc 180
ggccttacta tctgtcaaaa aataagggac aagcacacct atccgattat catgctgacc 240
gggaaagata cagaggtaga taaaattaca gggttaacaa tcggcgcgga tgattatata 300
acgaagccct ttcgcccact ggagttaatt gctcgggtaa aggcccagtt gcgccgatac 360
aaaaaattca gtggagtaaa ggagcagaac gaaaatgtta tcgtccactc cggccttgtc 420
attaatgtta acacccatga gtgttatctg aacgagaagc agttatccct tactcccacc 480
gagttttcaa tactgcgaat cctctgtgaa aacaagggga atgtggttag ctccgagctg 540
ctatttcatg agatatgggg cgacgaatat ttcagcaaga gcaacaacac catcaccgtg 600
catatccggc atttgcgcga aaaaatgaac gacaccattg ataatccgaa atatataaaa 660
acggtatggg gggttggtta taaaattgaa aaataa 696

<210> 19
<211> 1155
<212> DNA
<213> Enterococcus faecium

<400> 19
ttggttataa aattgaaaaa taaaaaaaac gactattcca aactagaacg aaaactttac 60
atgtatatcg ttgcaattgt tgtggtagca attgtattcg tgttgtatat tcgttcaatg 120
atccgaggga aacttgggga ttggatctta agtattttgg aaaacaaata tgacttaaat 180
cacctggacg cgatgaaatt atatcaatat tccatacgga acaatataga tatctttatt 240
tatgtggcga ttgtcattag tattcttatt ctatgtcgcg tcatgctttc aaaattcgca 300
aaatactttg acgagataaa taccggcatt gatgtactta ttcagaacga agataaacaa 360
attgagcttt ctgcggaaat ggatgttatg gaacaaaagc tcaacacatt aaaacggact 420
ctggaaaagc gagagcagga tgcaaagctg gccgaacaaa gaaaaaatga cgttgttatg 480
tacttggcgc acgatattaa aacgcccctt acatccatta tcggttattt gagcctgctt 540
gacgaggctc cagacatgcc ggtagatcaa aaggcaaagt atgtgcatat cacgttggac 600
aaagcgtatc gactcgaaca gctaatcgac gagtttttg agattacacg gtataaccta 660
caaacgataa cgctaacaaa aacgcacata gacctatact atatgctggt gcagatgacc 720
gatgaatttt atcctcagct ttccgcacat ggaaaacagg cggttattca cgcccccgag 780
gatctgaccg tgtccggcga ccctgataaa ctcgcgagag tctttaacaa cattttgaaa 840
aacgccgctg catacagtga ggataacagc atcattgaca ttaccgcggg cctctccggg 900
gatgtggtgt caatcgaatt caagaacact ggaagcatcc caaaagataa gctagctgcc 960
atatttgaaa agttctatag gctggacaat gctcgttctt ccgatacggg tggcgcggga 1020
cttggattgg cgattgcaaa agaaattatt gttcagcatg gagggcagat ttacgcggaa 1080
agcaatgata actatacgac gtttagggta gagcttccag cgatgccaga cttggttgat 1140
aaaaggaggt cctaa 1155

<210> 20
<211> 969
<212> DNA
<213> Enterococcus faecium

<400> 20
atgaataaca tcggcattac tgtttatgga tgtgagcagg atgaggcaga tgcattccat 60
gctctttcgc ctcgctttgg cgttatggca acgataatta acgccaacgt gtcggaatcc 120
aacgccaaat ccgcgccttt caatcaatgt atcagtgtgg gacataaatc agagatttcc 180
gcctctattc ttcttgcgct gaagagagcc ggtgtgaaat atatttctac ccgaagcatc 240
ggctgcaatc atatagatac aactgctgct aagagaatgg gcatcactgt cgacaatgtg 300
gcgtactcgc cggatagcgt tgccgattat actatgatgc taattcttat ggcagtacgc 360
aacgtaaaat cgattgtgcg ctctgtggaa aaacatgatt tcaggttgga cagcgaccgt 420
ggcaaggtac tcagcgacat gacagttggt gtggtgggaa cgggccagat aggcaaagcg 480
gttattgagc ggctgcgagg atttggatgt aaagtgttgg cttatagtcg cagccgaagt 540
atagaggtaa actatgtacc gtttgatgag ttgctgcaaa atagcgatat cgttacgctt 600
catgtgccgc tcaatacgga tacgcactat attatcagcc acgaacaaat acagagaatg 660
aagcaaggag catttcttat caatactggg cgcggtccac ttgtagatac ctatgagttg 720
gttaaagcat tagaaaacgg gaaactgggc ggtgccgcat tggatgtatt ggaaggagag 780
gaagagtttt tctactctga ttgcacccaa aaaccaattg ataatcaatt tttacttaaa 840
cttcaaagaa tgcctaacgt gataatcaca ccgcatacgg cctattatac cgagcaagcg 900
ttgcgtgata ccgttgaaaa aaccattaaa aactgtttgg attttgaaag gagacaggag 960
catgaatag 969

<210> 21
<211> 1032
<212> DNA
<213> Enterococcus faecium

<400> 21
atgaatagaa taaaagttgc aatactgttt gggggttgct cagaggagca tgacgtatcg 60
gtaaaatctg caatagagat agccgctaac attaataaag aaaaatacga gccgttatac 120
attggaatta cgaaatctgg tgtatggaaa atgtgcgaaa aaccttgcgc ggaatgggaa 180
aacgacaatt gctattcagc tgtactctcg ccggataaaa aaatgcacgg attacttgtt 240
aaaaagaacc atgaatatga aatcaaccat gttgatgtag cattttcagc tttgcatggc 300
aagtcaggtg aagatggatc catacaaggt ctgtttgaat tgtccggtat ccctttgta 360
ggctgcgata ttcaaagctc agcaatttgt atggacaaat cgttgacata catcgttgcg 420
aaaaatgctg ggatagctac tcccgccttt tgggttatta ataaagatga taggccggtg 480
gcagctacgt ttacctatcc tgtttttgtt aagccggcgc gttcaggctc atccttcggt 540
gtgaaaaaag tcaatagcgc ggacgaattg gactacgcaa ttgaatcggc aagacaatat 600
gacagcaaaa tcttaattga gcaggctgtt tcgggctgtg aggtcggttg tgcggtattg 660
ggaaacagtg ccgcgttagt tgttggcgag gtggaccaaa tcaggctgca gtacggaatc 720
tttcgtattc atcaggaagt cgagccggaa aaaggctctg aaaacgcagt tataaccgtt 780
cccgcagacc tttcagcaga ggagcgagga cggatacagg aaacggcaaa aaaaatatat 840
aaagcgctcg gctgtagagg tctagcccgt gtggatatgt ttttacaaga taacggccgc 900
attgtactga acgaagtcaa tactctgccc ggtttcacgt catacagtcg ttatccccgt 960
atgatggccg ctgcaggtat tgcacttccc gaactgattg accgcttgat cgtattagcg 1020
ttaaaggggt ga 1032

<210> 22
<211> 609
<212> DNA
<213> Enterococcus faecium

<400> 22
atggaaatag gatttacttt tttagatgaa atagtacacg gtgttcgttg ggacgctaaa 60
tatgccactt gggataattt caccggaaaa ccggttgacg gttatgaagt aaatcgcatt 120
gtagggacat acgagttggc tgaatcgctt ttgaaggcaa aagaactggc tgctacccaa 180
gggtacggat tgcttctatg ggacggttac cgtcctaagc gtgctgtaaa ctgttttatg 240
caatgggctg cacagccgga aaataacctg acaaaggaaa gttattatcc caatattgac 300
cgaactgaga tgatttcaaa aggatacgtg gcttcaaaat caagccatag ccgcggcagt 360
gccattgatc ttacgcttta tcgattagac acgggtgagc ttgtaccaat ggggagccga 420

tttgatttta tggatgaacg ctctcatcat gcggcaaatg gaatatcatg caatgaagcg 480
caaaatcgca gacgtttgcg ctccatcatg gaaaacagtg ggtttgaagc atatagcctc 540
gaatggtggc actatgtatt aagagacgaa ccatacccca atagctattt tgatttcccc 600
gttaaataa 609

<210> 23
<211> 912
<212> DNA
<213> Enterococcus faecium

<400> 23
atgaagaagt tgtttttttt attgttattg ttattcttaa tatacttagg ttatgactac 60
gttaatgaag cactgttttc tcaggaaaaa gtcgaatttc aaaattatga tcaaaatccc 120
aaagaacatt tagaaaatag tgggacttct gaaaataccc aagagaaaac aattacagaa 180
gaacaggttt atcaaggaaa tctgctatta atcaatagta aatatcctgt tcgccaagaa 240
agtgtgaagt cagatatcgt gaatttatct aaacatgacg aattaataaa tggatacggg 300
ttgcttgata gtaatattta tatgtcaaaa gaaatagcac aaaaattttc agagatggtc 360
aatgatgctg taaagggtgg cgttagtcat tttattatta atagtggcta tcgagacttt 420
gatgagcaaa gtgtgcttta ccaagaaatg ggggctgagt atgccttacc agcaggttat 480
agtgagcata attcaggttt atcactagat gtaggatcaa gcttgacgaa aatggaacga 540
gcccctgaag gaaagtggat agaagaaaat gcttggaaat acgggttcat tttacgttat 600
ccagaggaca aaacagagtt aacaggaatt caatatgaac catggcatat tcgctatgtt 660
ggtttaccac atagtgcgat tatgaaagaa aagaatttcg ttctcgagga atatatggat 720
tacctaaaag aagaaaaaac catttctgtt agtgtaaatg gggaaaaata tgagatcttt 780
tattatcctg ttactaaaaa taccaccatt catgtgccga ctaatcttcg ttatgagata 840
tcaggaaaca atatagacgg tgtaattgtg acagtgtttc ccggatcaac acatactaat 900
tcaaggaggt aa 912

<210> 24
<211> 486
<212> DNA
<213> Enterococcus faecium

<400> 24
ttgggaaaaa tattatctag aggattgcta gctttatatt tagtgacact aatctggtta 60
gtgttattca aattacaata caatatttta tcagtattta attatcatca aagaagtctt 120
aacttgactc catttactgc tactgggaat ttcagagaga tgatagataa tgttataatc 180
tttattccat ttggcttgct tttgaatgtc aattttaaag aaatcggatt tttacctaag 240
tttgcttttg tactggtttt aagtcttact tttgaaataa ttcaatttat cttcgctatt 300
ggagcgacag acataacaga tgtaattaca aatactgttg gaggctttct tggactgaaa 360
ttatatggtt taagcaataa gcatatgaat caaaaaaaat tagacagagt tattattttt 420
gtaggtatac ttttgctcgt attattgctc gtttaccgta cccatttaag aataaattac 480
gtgtaa 486

<210> 25
<211> 19
<212> DNA
<213> Enterococcus faecium

<400> 25
cgaataccgc aagcgacag 19

<210> 26
<211> 663
<212> DNA
<213> Enterococcus faecium

<400> 26
atgtcgatac gaattctact tgtcgaggat gatgatcata tctgcaatac agtaagggcg 60
tttttggctg aagcaagata tgaggtggat gcctgcacag atggaaacga agcacacacc 120
aagttctatg aaaacaccta tcaactggtt attcttgata ttatgctgcc cggtatgaat 180
gggcatgaac ttctacgtga atttcgggcg caaaatgata cccccattct gatgatgaca 240
gccctgtcgg atgacgaaaa ccaaatccgg gcgtttgatg cagaggcaga cgactatgta 300
acaaagccat tcaagatgcg gattttacta aagcgggtgg aagccctgtt acggcgcagc 360
ggtgcgctgg caaaggaatt tcgtgtgggc aggctgacac ttctgccgga ggattttagg 420
gtactttgtg acggtacgga gctgcccctg acacgaaaag aatttgaaat ccttttgctg 480
ctggtgcaga acaaaggcag aaccttaacc catgaaatca ttttgtcccg catatgggga 540
tatgactttg acggtgatgg cagcacagtc cacactcata tcaaaaatct gcgggcgaag 600
ctgccggaaa atatcatcaa aaccatccgc ggtgtaggtt accgattgga ggaatcatta 660
taa 663

<210> 27
<211> 1344
<212> DNA
<213> Enterococcus faecium

<400> 27
atggaaagaa aagggatttt cattaaggtt ttttcctata cgatcattgt cctgttactg 60
cttgtcggtg taacggcaac actgtttgca cagcaatttg tgtcttattt cagagcgatg 120
gaagcacagc aaacagtaaa atcctatcag ccattggtgg aactgattca gaatagcgat 180
aggcttgata tgcaagaggt ggcagggctg tttcactaca ataaccaatc ctttgagttt 240
tatattgaag ataaagaggg aagcgtactc tatgccacac cgaatgccga tacatcaaat 300
agtgttaggc ccgactttct ttatgtggta catagagatg ataatatttc gattgttgct 360
caaagcaagg caggtgtggg attgctttat caagggctga caattcgggg aattgttatg 420
attgcataa tggttgtatt cagcctttta tgcgcgtata tctttgcgcg gcaaatgaca 480
acgccgatca aagccttagc ggacagtgcg aataaaatgg caaacctgaa agaagtaccg 540
ccgccgctgg agcgaaagga tgagcttggc gcactggctc acgacatgca ttccatgtat 600
atcaggctga aagaaaccat cgcaaggctg gaggatgaaa tcgcaaggga acatgagttg 660
gaggaaacac agcgatattt ctttgcggca gcctctcatg agttaaaaac gcccatcgcg 720
gctgtaagcg ttctgttgga gggaatgctt gaaaatatcg gtgactacaa agaccattct 780
aagtatctgc gcgaatgcat caaaatgatg gacaggcagg gcaaaaccat ttccgaaata 840
ctggagcttg tcagcctgaa cgatgggaga atcgtaccca tagccgaacc gctggacata 900
gggcgcacgg ttgccgagct gctacccgat tttcaaacct tggcagaggc aaacaaccag 960
cggttcgtca cagatattcc agccggacaa attgtcctgt ccgatccgaa gctgatccaa 1020
aaggcgctat ccaatgtcat attgaatgcg gttcagaaca cgccccaggg aggtgaggta 1080
cggatatgga gtgagcctgg ggctgaaaaa taccgtcttt ccgttttgaa catgggcgtt 1140
cacattgatg atactgcact ttcaaagctg ttcatcccat tctatcgcat tgatcaggcg 1200
cgaagcagaa aaagtgggcg aagcggtttg gggcttgcca tcgtacaaaa aacgctggat 1260
gccatgagcc tccaatatgc gctggaaaac acctcagatg gcgttttgtt ctggctggat 1320
ttaccgccca catcaacact ataa 1344

<210> 28
<211> 807
<212> DNA
<213> Enterococcus faecium

<400> 28
atggaaaaaa gcaactatca ttccaatgtg aatcatcaca aacggcatat gaaacaatct 60
ggggaaaaac gggcttttct atgggcgttc attatctcgt tcacagtctg cacgctgttt 120
ttggggtgga gattggtttc cgtattggag gcaacacagc taccgcccat ccctgcaact 180
catacaggca gcgggactgg tgtagcggag aatccagagg aaaacactct tgccaccgcc 240
aaagaacagg gagatgaaca ggaatggagc ctgattttag tgaacaggca gaaccccatc 300
cccgcccagt acgatgtgga acttgagcag ctgtcaaatg gtgagcggat agacattcgg 360
atttctccct acctccagga tttgtttgat gccgcaagag ctgatggagt ttacccgatt 420

gtcgcatccg gataccggac aacagaaaaa cagcaagaaa tcatggatga aaaagtcgcc 480
gaatacaagg cgaaaggcta cacctctgca caggctaaag cggaagcaga aacttgggtg 540
gccgtgccgg gaacaagcga gcatcagctt ggtcttgctg tggatatcaa tgcggatgga 600
attcattcaa ccggcaacga ggtttacaga tggctggatg aaaacagcta tcgctttggt 660
tttattcgcc gctacccgcc agacaagaca gagataaccg gtgtgagcaa cgagccgtgg 720
cattaccgat atgtcggcat cgaagctgcc acaaagatat accaccaagg gctttgcctt 780
gaggaatatt taaacacaga aaaatga 807

<210> 29
<211> 972
<212> DNA
<213> Enterococcus faecium

<400> 29
atgagaaaaa gtatgggcat tactgttttt ggatgcgagc aggatgaggc aaatgctttc 60
cgcaccttat caccagattt tcatattatc cctacgctga tcagtgatgc gatatcggca 120
gacaacgcaa aattggccgc tggcaatcaa tgcattagcg taggccataa gtccgaggtt 180
tccgaggcga caattcttgc gctgagaaag gtcggggtaa aatacatttc tacccgcagc 240
atcggctgca atcacattga tacgactgcc gccgagagaa tggggatctc ggttggcaca 300
gttgcgtatt cgccggacag cgttgcggat tatgctttga tgctgatgct gatggccata 360
cggggtgcaa agtccaccat acacgccgtg gcgcaacaaa atttcagact ggattgtgtc 420
cgggggaaag agctgcggga tatgactgtg ggagttattg gaaccggcca tatagggcaa 480
gcggtcgtca aaaggctgcg gggatttgga tgccgtgtgc tagcctatga taacagccga 540
aaaattgagg cagattatgt ccagcttgat gagcttctaa aaaacagcga tattgttacg 600
ctccatgtgc cgctttgtgc ggatacccgc catctgatcg gccagagcga aatcggagag 660
atgaagcaag gcgcattttt aatcaacact gggcgcgggg cgcttgtcga taccgggtcg 720
ctggtggagg cactgggaag cggaaagctg ggcggtgcgg cactggatgt gttggagggc 780
gaggatcagt ttgtttatac cgactgctcg cagaaagtgc ttgaccatcc ctttttgtcg 840
cagctcctaa ggatgccaaa tgtgatcatc acaccccata cggcgtacta caccgagcgt 900
gtgctgcgag ataccacaga aaaaacaatc aggaattgtc ttaactttga aaggagttta 960
cagcatgaat aa 972

<210> 30
<211> 1029
<212> DNA
<213> Enterococcus faecium

<400> 30
atgaataaaa taaaagtcgc aattatcttc ggcggttgct cggaggaaca tgatgtgtcg 60
gtaaaatccg caatagaaat tgctgcgaac attaatactg aaaaattcga tccgcactac 120
atcggaatta caaaaaacgg cgtatggaag ctatgcaaga agccatgtac ggaatgggaa 180
gccgatagtc tccccgccat attctccccg gataggaaaa cgcatggtct gcttgtcatg 240
aaagaaagag aatacgaaac tcggcgtatt gacgtggctt tcccggtttt gcatggcaaa 300
tgcggggagg atggtgcgat acagggtctg tttgaattgt ctggtatccc ctatgtaggc 360
tgcgatattc aaagctccgc agcttgcatg gacaaatcac tggcctacat tcttacaaaa 420
aatgcgggca tcgccgtccc cgaatttcaa atgattgaaa aaggtgacaa accggaggcg 480
aggacgctta cctaccctgt ctttgtgaag ccggcacggt caggttcgtc ctttggcgta 540
accaaagtaa acagtacgga agaactaaac gctgcgatag aagcagcagg acaatatgat 600
ggaaaaatct taattgagca agcgatttcg ggctgtgagg tcggctgcgc ggtcatggga 660
aacgaggatg atttgattgt cggcgaagtg gatcaaatcc ggttgagcca cggtatcttc 720
cgcatccatc aggaaaacga gccggaaaaa ggctcagaga atgcgatgat tatcgttcca 780
gcagacattc cggtcgagga acgaaatcgg gtgcaagaaa cggcaaagaa agtatatcgg 840
gtgcttggat gcagagggct tgctcgtgtt gatcttttt tgcaggagga tggcggcatc 900
gttctaaacg aggtcaatac cctgcccggt tttacatcgt acagccgcta tccacgcatg 960
gcggctgccg caggaatcac gcttcccgca ctaattgaca gcctgattac attggcgata 1020
gagaggtga 1029

<210> 31
<211> 609
<212> DNA
<213> Enterococcus faecium

<400> 31
atggaaaatg gttttttgtt tttagatgaa atgttgcatg gtgttcgttg ggatgccaag 60
tacgctacat gggataactt cacgggaaaa ccagtggatg ggtatgaggt gaatcgcatc 120
atcggcacaa aggccgtggc gcttgctctg cgcgaagcac aaatccatgc ggcacgcctt 180
ggctacggct tgcttttatg ggatggatat cggccaaaat ctgcggtgga ctgtttcctg 240
cgttgggcgg cgcagccgga ggacaacctc acaaaagaaa aatattaccc caatattgag 300
cgagccgagt tgattacaaa gggctatgtg gcctcacaat ccagccatag ccgtggaagc 360
acaattgatc ttacgctcta ccacttggat acaggggaac ttgtttcaat gggaagcaac 420
ttcgatttta tggacgaacg gtcgcaccat acagcaaaag ggatagggaa tgcagaggca 480
caaaatcgaa gatgcttgcg taaaatcatg gaaagcagcg gatttcagtc ctatcgcttt 540
gaatggtggc actataagtt gattgatgag ccataccccg atacctattt taattttgct 600
gtttcataa 609

<210> 32
<211> 828
<212> DNA
<213> Enterococcus faecium

<400> 32
atgaacagaa aaagattgac acagcgcttc ccgttcctgc ttccaatgag acaagcgcag 60
agaaaaatat gcttttatgc gggaatgaga tttgacggct gttgctatgc acagacgata 120
ggagaaaaaa cgcttcccta tttgctcttt gaaacggatt gtgcgttata caaccacaat 180
accggatttg acatgatata ccaagaaaac aaggtgttca acttaaagct ggcggcaaag 240
accttaaacg gcctattgat aaaaccgggg gaaacctttt ctttctggcg gctggtacgc 300
catgcggaca aagataccc ctataaagac ggccttacgg tggccaatgg taagctcacc 360
accatgtcgg gcggcggtat gtgccagatg agcaatttac tattttgggt gttcctgcat 420
acgccattga caattatcca gcgcagcggt cacgtagtaa aggagtttcc agagccaaac 480
agtgacgaga tcaaaggggt ggatgcaacc atctcagagg gctggattga tttaaaagtg 540
cgaaacgata ccgactgcac ctaccaaata tgggtgaccc tagatgatga gaaaatcatc 600
ggtcaggtgt tcgccgacaa acagcctcaa gcattataca aaattgcaaa cggcagtatt 660
cagtatgtcc gtgaaagtgg cgggatttat gaatatgcca aggttgaacg gatgcaagtt 720
gccttaggta ccggggaaat aatagattgc aagctgcttt atacaaacaa atgcaaaatc 780
tgctatcccc tcccggaaag tgtggatatt caggaggcga accaatga 828

<210> 33
<211> 1053
<212> DNA
<213> Enterococcus casseliflavus

<400> 33
atgaaaaaaa tcgccattat ttttggaggc aattcaccgg aatacaccgt ttctttagct 60
tcagcaacta gcgcaatcga agcactccaa tcatctccct atgactacga cctctctttg 120
atcgggatcg ccccagatgc tatggattgg tacttgtata caggagaact ggaaaacatc 180
cgacaagaca cgtggttgtt ggatacgaaa cataaacaga aaatacagcc gctattcgaa 240
ggaaacggct tttggctaag tgaagagcag caaacgttgg tacctgatgt tttatttccc 300
attatgcatg gcaaatacgg ggaagatggc agtatccaag gattgtttga attgatgaag 360
ctgccttatg taggctgcgg ggtggcaggt tctgccttat gtatgaacaa atggctgctg 420
catcaagctg cagcagccat tggcgtacaa agtgctccta cgattctctt gacaaatcaa 480
gccaaccagc aagaacaaat cgaagctttt atccagaccc atggcttccc agttttcttt 540
aagcctaatg aagcgggctc ctcaaaaggg atcactaaag tcacctgcgt tgaagaaatc 600
gcttctgcct taaaagaagc ctttacttat tgttccgcag tgctcctaca aaaaaatatt 660
gccggtgttg agatcggttg cggtattttg ggcaacgact ctttgactgt cggtgcttgt 720

gacgccattt cattagtaga cggctttttc gattttgaag aaaagtacca gctgatcagc 780
gccaaaatca ccgtccctgc gccattgcct gaaacgattg aaaccaaggt caaagaacaa 840
gctcagctgc tctatcgtag tcttggtctt aaaggtcttg ctcgcatcga ctttttttgtc 900
acggagcgag gagaactata cttgaatgaa atcaatacta tgccgggctt tacgagtcac 960
tcccgctatc ctgccatgat ggcagcggtc ggcttatcct atcaagaact actacaaaaa 1020
ctgcttgtct tagcaaagga ggaagtcaaa tga 1053

<210> 34
<211> 699
<212> DNA
<213> Enterococcus faecium

<400> 34
atgaatgaaa aaatcttagt ggttgatgat gaaaaagaat tggccgactt agttgaagta 60
tatctgaaaa acgatggata taccgtttat aaattttata atggcaagga tgcactaaag 120
tgtattgaat ccgtggaact ggatttagcc atattggata tcatgcttcc ggatgtagac 180
gggtttcaga tctgccagaa aatccgggaa aagttttact tccctgttat catgctgaca 240
gcaaaagtgg aggacgggga taaaatcatg ggactgtccg tggcggatga ttatattaca 300
aagccgttta acccgctgga agtggttgcg agagtaaagg cgcagctgcg gcagtacatg 360
cggtacaagc agcccagctt aaagcaggag gctgaatgca cagaatacga tatcagaggg 420
atgacaatca gcaagagcag ccataagtgt atcctgtttg gaaaggagat tcagctgacg 480
ccaacggagt tttcgattct ttggtatctg tgcgagcgtc agggtacggt tgtttctacg 540
gaggaattat ttgaggcagt atggggtgaa cggtttttg acagcaataa tactgtgatg 600
gcgcatatcg ggcggctccg ggagaaaatg aaggaaccgt caagaaatcc gaaatttata 660
aaaactgtgt ggggagtggg atataccatt gaaaaatag 699

<210> 35
<211> 1146
<212> DNA
<213> Enterococcus faecium

<400> 35
ttgaaaaata gaaataaaac cagtcatgaa gatgactatt tacttttaa aaacagattg 60
tccgttaaaa tactgcttat gatggtatat tccattctga ttattgcggg tgtttatctg 120
tttatcttaa aagataattt tgcaaatgtc gtggtagcca ttttagacag ctttatctat 180
catgatcggg atgaggcggt ggctgtttat ctgagaacct ttaaggcgtc tgagatatgg 240
cttttcctga tagcggttat gggcgtgttt tttatgatct tccgccgtta tctggacagt 300
atttcaaaat attttaagga gatcaaccgg gggatcgata ctttggtgaa tgaggatgcc 360
aacgatattg ggctgcctcc ggagttggct tcgaccgaaa gaaaaatcaa ttccatacgg 420
catacctga cgaaacggaa aacggacgct gagcttgcag agcaaaggaa aaacgatctt 480
gtcatgtatc tggcccatga cctgaagacc ccgcttccat cggtcatagg atatttgaac 540
ctgttaaggg atgagaatca gatttccgag gaacttaggg aaaaatattt gtccatatca 600
ttggataagg ctgagcgtct ggaagaactg attaatgagt tttttgaaat tacgaggttt 660
aatctttcaa acatcacgct tgtgtacagc aaaatcaatc tgacgatgat gctggaacag 720
ctggggtatg agtttaagcc gatgctggcc gggaaaaatc tgaaatgtga atttgatgtt 780
cagccagaca tgatgctgtc ctgcgatgcc aacaagctgc agcgggtctt cgataatgtg 840
ctgagaaatg ccgtcagcta ctgctatgag aataccacca ttcgggtgaa agccaggcag 900
accgaagacc atgtactcat caaaatcata aacgaagggg atacgattcc tggggagaga 960
ttggaaagaa tctttgagca gttttaccgc ctggatgtat ctcgaagctc aagtaccggc 1020
ggggccggtc tggggcttgc cattgcaaaa gagattgtgg aactgcacca tggacagatc 1080
actgcccaca gcgaaaatgg tatcaccagt tttgaggtta cattgcccgt cgtaggaaaa 1140
tcgtaa 1146

<210> 36
<211> 1071
<212> DNA
<213> Enterococcus faecium

<400> 36

atgatggaat atcaaaacaa taatggaaac tatgacaaaa ggaatcgtag aaaagccaaa 60
aaaagaaaat tgctttttta cagggctgca tgtgtcacac tttgtttgct cattgtttct 120
gtaatctttg gagttgtgca ttttttaggg gagagtaaag atcccggcct tttatccaaa 180
gaaaacacaa aaacagacaa gaactattcg tggcttaccg acgatcagaa tgaggcagta 240
ccctcagttc cagagccagc catatccgac caggctaaca aaatttcggt aaatatcaca 300
gcggcaaacg ccattgtaat gaataaagac acaaatgagg tattgtacca gaaaaaaagc 360
acagccaaaa ttgcgccggc cagcactgct aagatgatta tggctttgac agcacttgac 420
tattgttccc cggaggatga aatgaaagta ggtgcggaga ttggaatgat tcaaagcgat 480
tcgtcaaccg catggcttat gaagggtgat acactgactg tcagacagct cctgattgcc 540
cttatgcttc cgtccggcaa tgatgcagcc tatacccttg cagtcaatac cggaaaggct 600
attgcaggtg ataacagcct gaccagtcag caagcgattg aagtattcat ggataaggta 660
aatgaaaaag ccgtggccct tggcgccaca aactcgaaat ttgtagctcc ggatggatat 720
gatgccgaag ggcagtatac tacagcttat gaccttgcta tcattgcaaa agcatgtttg 780
gacaatccta tcatttcgga gattgtagcg agttattcat cctatgaaaa atggtcaaac 840
ggaagagagg tcacttacaa caattccaat gagcttctcg atccgaacag tccctattac 900
cgtccggagg ttatcggttt gaaaacagga accagcagtc ttggcggcgc atgtattgtt 960
tctgcagcgg tgatggacgg agaaacctat atctgtgtag ttatgggttc tacaaaggaa 1020
agcaggtttc aggacagcgt tgatatttta gataaaatca aagcccagta a 1071

<210> 37
<211> 969
<212> DNA
<213> Enterococcus faecium

<400> 37

atggagaaaa taatagacat aactgttttt ggctgcgagc cagacgaaat ggaggttttt 60
caaaagattt cttatgagct tggtgttaca gccacactca taaaagattc tatatcagaa 120
agcaatgctg gattagctaa tggatgccgg tgtgtaagcg taagccataa agcggagcta 180
tcagaaccga ttcttcttgc gctaaaaaat gcaggggtaa aatatatcag tacccggagc 240
attggtttta accatattga tatacaggcg gctgggttac tgggtatggt tgttggcaca 300
gtagaatact cgccgggaag tgtggccgat tataccgtca tgctgatgct tatgctgatg 360
cgtggcacaa agtcgattct gcgtgaaacc cagaggcaga attattgcct gaatgacctg 420
cgcggaaaag aactgcggga tatgaccgtg ggtgtgttag gaactgggcg aatcggacag 480
gcagtcatgg agcgcctgga gggattcggt tgtaaggtat tggcgtatga ccgaaatcaa 540
aaagcaggag cagactatgt ttcgtttcat gaactgctga aaaaaagtga cattgttaca 600
ctgcatatcc cgttggcgga ggatacccgc catatgattg gctatgaaga gctggaaatg 660
atgaaggaag aggcgcttct gatcaataca gggcggggcg ctttagtgga taccgcagca 720
ttggtagaag cattaaaagg acagaaaatc ggcggcgccc tggatgtttt ggaaggcgaa 780
gaaggtatct tttaccatga ctgcacccaa agaagaatag aacatccttt cctgtcggtc 840
ctgcagggaa tgccgaatgt cattgttacg ccgcacacag cctatcatac ggaacgggtg 900
ttggttgaca cggtcagaaa tactattaga aattgtttga attttgaaag gagtctggga 960
aatgtttag 969

<210> 38
<211> 1032
<212> DNA
<213> Enterococcus faecium

<400> 38

atgtttagaa ttaaagttgc agttctgttt gggggctgtt cagaggaaca taatgtttcg 60
ataaaatctg cgatggagat tgccgcaaac atagatacaa aaaaatatca gccttattat 120
attggaatca caaaatccgg cgtttggaaa atgtgtgaaa aaccttgttt ggagtgggaa 180
caatatgcgg gggatccggt tgtttttttcg ccggacagaa gtacgcatgg tctgctgata 240
caaaaagaca aagggtatga aatccagcct gtggatgtgg tgtttccgat gattcatggc 300
aagtttgggg aggatggctc catacaaggc ttgcttgaat tgtcaggcat tccgtatgtg 360

ggatgcgata ttcaaagctc cgtgatctgc atggataagg cgcttgcata taccgttgtg 420
aaaaatgcgg gtatcactgt gcctgggttc cggatccttc aggaggggga tcgcctggaa 480
acggaggatt tcgtatatcc cgtttttgta aagcctgccc gttccggctc atcctttggc 540
gtaaacaagg tatgcaaggc agaagaactg caggcagcaa tcgaagaagc aagaaaatat 600
gacagcaaga ttttgattga agaggccgtt accgggagtg aggtaggctg cgccatactg 660
ggaaacggaa atgatctcat ggctggcgag gtggatcaga ttgagctgag acacggcttt 720
tttaagattc atcaggaagc acagccggag aagggatctg aaaatgcagt catccgagtt 780
ccagccgcct taccggatga ggtaagagaa cagattcagg aaacggcaat gaagatttac 840
cggatacttg gctgcagagg attggcccgc attgacctgt ttttgcggga ggacggttgc 900
attgtgctga atgaagtgaa taccatgcca ggttttactt cctacagccg ctatccccgc 960
atgatgacag cagccggttt tacgctttct gaaatactgg atcgcttgat tgaactttca 1020
cttaggaggt aa 1032

<210> 39
<211> 609
<212> DNA
<213> Enterococcus faecium

<400> 39
atgaaaaaga actttgcctt tttagatgaa atgattcccg ggatccgatg ggatgccaaa 60
tatgccacct gggacaattt caccgggaaa ccggtagacg gatacatggt aaaccgtgtt 120
atgggaacga aggagctggg agttgctttg cgtaaggctc agaagatggc ggagaagcta 180
ggatatggtt tgctcttatg ggacggctat cgcccccagt gcgcagtgaa ttgttttctg 240
aattgggctt cccaaccgga agacaatctg acgaaaaagc gttactatcc aaatatcaaa 300
aggaatgaga tggttgcgaa ggggtatgtg gcctcacaat ccagccacag ccgtggaagt 360
acggttgacc ttacaatttt tcatttgaat agcggtatgc ttgttcctat gggtggagat 420
tttgacttta tggatgaacg gtcacaccat gccgcaagcg gtctgagcga agaagaatca 480
aaaaaccggc agtgcttgcg ttatatcatg gagagtagcg gatttgaagc ctatcgttat 540
gaatggtggc attacgtctt ggcggacgag ccatacccgg atacatattt tgatttttgc 600
attgcctag 609

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 February 2001 (22.02.2001)

PCT

(10) International Publication Number
WO 01/12803 A3

(51) International Patent Classification[7]: C07K 14/315, C12N 15/11, 15/52

(21) International Application Number: PCT/US00/22086

(22) International Filing Date: 11 August 2000 (11.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/149,313 17 August 1999 (17.08.1999) US

(71) Applicant *(for all designated States except US)*: **BETH ISRAEL DEACONESS MEDICAL CENTER, INC.** [US/US]; 1 Deaconess Road, Boston, MA 02215 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **INOUYE, Roger, T.** [US/US]; 23 Roberts Road, Wellesley, MA 02481 (US). **TORRES-VIERA, Carlos** [VE/VE]; Calle Andrea de Ledesma, Qta La Torrera, Urb Sorocaima, Caracas, Venezuela (VE). **MOELLERING, Robert** [US/US]; 49 Longfellow Road, Wellesley Hills, MA 02481-5220 (US). **GOLD, Howard** [US/US]; Apartment 610, 135 Pleasant Street, Brookline, MA 02446-3489 (US). **ELIOPOULOS, George, M.** [US/US]; 5 Laurel Circle, Needham, MA 02494 (US).

(74) Agent: **PLUMER, Elizabeth, R.**; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(81) Designated States *(national)*: CA, JP, US.

(84) Designated States *(regional)*: European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

**Published:**
— *with international search report*

(88) Date of publication of the international search report:
18 October 2001

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 01/12803 A3

(54) Title: METHODS AND COMPOSITIONS FOR RESTORING ANTIBIOTIC SUSCEPTIBILITY IN GLYCOPEPTIDE-RESISTANT *ENTEROCOCCUS*




(57) Abstract: Methods and compositions for reducing vancomycin resistance in a vancomycin resistant organism is provided. The methods involve delivering to the organism an isolated nucleic acid molecule that hybridizes to a target vancomycin gene and/or that serves as a *VanR*-responsive promoter decoy.

# INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/22086

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07K14/315 C12N15/11 C12N15/52

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, WPI Data, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|---|---|---|
| X<br>Y | WO 92 07942 A (PASTEUR INSTITUT)<br>14 May 1992 (1992-05-14)<br>the whole document, in particular pages 7, 46 and 51 | 24-27,29<br>1-6,8, 10-17,19 |
| | --- | |
| Y | WO 90 00624 A (BAYLOR COLLEGE MEDICINE)<br>25 January 1990 (1990-01-25)<br>the whole document, in particular page 4 line 7 to page 5 line 25 | 1-17,19 |
| | --- | |
| A | PETER MITCHELL: "Facing up to antibiotic resistance"<br>PHARMAPROJECTS MAGAZINE,<br>vol. 3, no. 8, June 1998 (1998-06), pages 16-20, XP000943900<br>the whole document, in particular pages 18-19 | 1-23,28 |
| | --- | |
| | -/-- | |

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

| Date of the actual completion of the international search | Date of mailing of the international search report |
|---|---|
| 5 March 2001 | 18.04.01 |

| Name and mailing address of the ISA | Authorized officer |
|---|---|
| European Patent Office, P.B. 5818 Patentlaan 2<br>NL - 2280 HV Rijswijk<br>Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,<br>Fax: (+31-70) 340-3016 | Julia, P |

4

Form PCT/ISA/210 (second sheet) (July 1992)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|---|---|---|
| A | WO 98 12205 A (VIRUS RESEARCH INST INC ;BEATTIE DAVID T (US)) 26 March 1998 (1998-03-26) page 3 last paragraph to page 4 first paragraph | 1-23,28 |
| X | WO 96 08582 A (BERGERON MICHEL G ;OUELLETTE MARC (CA); ROY PAUL H (CA)) 21 March 1996 (1996-03-21) the whole document, in particular page 17, page 24 example 9, page 26 example 13 and Table 8 | 24-26 |
| P,X | DATABASE GALE GROUP NEWSLETTER DB [Online] D.J. DENOON: "Gene-Based strategy reverses vancomycin resistance" XP002154962 Database accession number 56646980 abstract & Gene Therapy Weekly 1999, Oct 18 | 1-6, 10-23,28 |
| Y | STEFAN EVERS AND PATRICE COURVALIN: "Regulation of VanB-type vancomycin resistance gene expression by the VanSB-VanRB two-component regulatory system in Enterococcus faecalis V583" JOURNAL OF BACTERIOLOGY, vol. 178, no. 5, March 1996 (1996-03), pages 1302-1309, XP002153486 US the whole document | 1-5,7, 13-15 |
| X | WO 94 14961 A (PASTEUR INSTITUT ;ARTHUR MICHEL (FR); DUTKA MALEN SYLVIE (FR); EVE) 7 July 1994 (1994-07-07) | 24,25,27 |
| Y | the whole document, in particular pages 6 and 8-10 | 1-5,7, 13-15 |
| Y | F. NAVARRO AND P. COURVALIN: "Analysis of genes encoding D-alanine-D-alanine ligase-related enzymes in Enterococcus casseliflavus and Enterococcus flavescens" ANTIMICROB AGENTS CHEMOTHER, vol. 38, no. 8, August 1994 (1994-08), pages 1788-1793, XP000984075 the whole document | 1-5,8, 13-15 |

-/--

4

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|---|---|---|
| Y | B. CASADEWALL AND P. COURVALIN: "Characterization of the VanD glycopeptide resistance gene cluster from Enterococcus faecium BM4339" JOURNAL OF BACTERIOLOGY, vol. 181, no. 12, June 1999 (1999-06), pages 3644-3648, XP002153485 US the whole document | 1-5,9, 13-15 |
| X | WO 99 01571 A (MODRUSAN ZORA D ;ID BIOMEDICAL CORP (CA)) 14 January 1999 (1999-01-14) thw whole document, in particular claim 4 | 24-27 |
| X | M. ARTHUR ET AL., : "Regulated interactions between partner and non-partner sensors and response regulators that control glycopeptide resistance gene expression in enterococci" MICROBIOLOGY, vol. 145, no. PT8, August 1999 (1999-08), pages 1849-1858, XP000986365 the whole document, in particular paragraph bridging pages 1856-1857 and figure 2d | 20,22 |
| Y | GRISSOM-ARNOLD J ET AL: "INDUCTION OF VANA VANCOMYCIN RESISTANCE GENES IN ENTEROCOCCUS FAECALIS: USE OF A PROMOTER FUSION TO EVALUATE GLYCOPEPTIDE AND NONGLYCOPEPTIDE INDUCTION SIGNALS" MICROBIAL DRUG RESISTANCE,LIEBERT,US, vol. 3, no. 1, 1997, pages 53-64, XP000944092 ISSN: 1076-6294 the whole document, in particular page 61 rigth column | 20,22 |
| Y | MOELLERING R C: "ANTIBIOTIC RESISTANCE: LESSONS FOR THE FUTURE" CLINICAL INFECTIOUS DISEASES,THE UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL,US, vol. 27, no. SUPP. 01, August 1998 (1998-08), pages S135-S140, XP000943873 ISSN: 1058-4838 the whole document, in particular page S138 rigth column last paragraph and page 139 rigth column | 20,22 |

-/--

4

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|---|---|---|
| A | ARTHUR M ET AL: "THE VANS-VANR TWO-COMPONENT REGULATORY SYSTEM CONTROLS SYNTHESIS OF DEPSIPEPTIDE PEPTIDOGLYCAN PRECURSORS IN ENTEROCOCCUS FAECIUM BM4147" JOURNAL OF BACTERIOLOGY,WASHINGTON, DC,US, vol. 174, no. 8, April 1992 (1992-04), pages 2582-2591, XP000944110 ISSN: 0021-9193 cited in the application the whole document, in particular page 2587 left column and page 2588 left column second full-paragraph<br>---- | 20,22 |

4

# INTERNATIONAL SEARCH REPORT

Int itional application No.
PCT/US 00/22086

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 1-23 as far as they comprise in vivo (therapeutic) methods, are directed to methods of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. [ ] Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. [X] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[X] No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-5, 13-15, 24-27, 29 (partial) and 6, 10-12, 16-17, 19 (complete)

a method for reducing vancomycin resistance in a vancomycin-resistant organism comprising introducing into the organism at least one anti-sense vancomycin resistance molecule under conditions to inhibit expression of a vancomycin resistance gene, wherein said vancomycin resistant organism is a vanA resistant organism and the anti-sense molecule is selected from the group consisting of a vanA antisense molecule, a vanR antisense molecule, a vanS antisense molecule, a vanH antisense molecule, a vanX antisense molecule, a vanY antisense molecule and a vanZ antisense molecule. Said method wherein the anti-sense vancomycin resistance molecule hybridizes to the complete vanA gene sequence or to a conserved region (from 10 to 30 nucleotides) thereof (encodes an active site of the ligase) or to the complete vanX gene sequence or to a conserved region thereof. Said method wherein introducing the anti-sense vancomycin resistance molecule comprises contacting the vancomycin resistant organism with at least one vector (enterococcal shuttle vector, bacteriophage, peptide nucleic acid molecule, enterococcal conjugative transposon or a pheromone-responsive plasmid) comprising one or more vanA "anti-sense vancomycin resistance molecules" under conditions to allow the vector to enter the organism and inhibit expression of one or more vancomycin resistance genes.

An isolated nucleic acid that hybridizes under stringent conditions to a nucleic acid molecule selected from the VanA resistance/VanA gene cluster of SEQ ID No.: 1 (which includes vanR, SEQ ID No.: 18; vanS, SEQ ID No.: 19; vanH, SEQ ID No.: 20; vanA, SEQ ID No.: 21; vanX, SEQ ID No.: 22; vanY, SEQ ID No.: 23; vanZ, SEQ ID No.: 24 and conserved sequences thereof) SEQ ID No.: 5-10. A vector comprising said isolated nucleic acid and an isolated vancomycin resistant organism comprising such a vector.

2. Claims: 1-5, 13-15, 24-27, 29 (partial) and 7 (complete)

Same method as invention group 1, but wherein said vancomycin resistant organism is a vanB resistant organism and the anti-sense molecule is selected from the group consisting of a vanRB antisense molecule, a vanSB antisense molecule, a vanYB antisense molecule, a vanW antisense molecule, a vanHB antisense molecule and a vanXB antisense molecule.

An isolated nucleic acid that hybridizes under stringent

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

conditions to a nucleic acid molecule selected from the VanB resistance/VanB gene cluster of SEQ ID No.: 2 (which includes vanRB, SEQ ID No.: 26; vanSB, SEQ ID No.: 27; vanYB, SEQ ID No.: 28; vanHB, SEQ ID No.: 29; vanB, SEQ ID No.: 30; vanXB, SEQ ID No.: 31; vanW, SEQ ID No.: 32 and conserved sequences thereof) SEQ ID No.: 11-12. A vector comprising said isolated nucleic acid and an isolated vancomycin resistant organism comprising such a vector.

3. Claims: 1-5, 13-15, 24-27, 29 (partial) and 8 (complete)

Same method as invention group 1, but wherein said vancomycin resistant organism is a vanC resistant organism and the anti-sense molecule is selected from the group consisting of a vanC antisense molecule or vanC-2.

An isolated nucleic acid that hybridizes under stringent conditions to a nucleic acid molecule selected from the VanC resistance (SEQ ID No.: 3) mediated by vanC-2 gene (SEQ ID No.: 33). A vector comprising said isolated nucleic acid and an isolated vancomycin resistant organism comprising such a vector.

4. Claims: 1-5, 13-15, 24-27, 29 (partial) and 9 (complete)

Same method as invention group 1, but wherein said vancomycin resistant organism is a vanD resistant organism and the anti-sense molecule is selected from the group consisting of a vanD antisense molecule, a vanRD antisense molecule, a vanSD antisense molecule, a vanYD antisense molecule, a vanHD antisense molecule and a vanXD antisense molecule.

An isolated nucleic acid that hybridizes under stringent conditions to a nucleic acid molecule selected from the VanD resistance/VanD gene cluster of SEQ ID No.: 4 (which includes vanRD, SEQ ID No.: 34; vanSD, SEQ ID No.: 35; vanYD, SEQ ID No.: 36; vanHD, SEQ ID No.: 37; vanD, SEQ ID No.: 38; vanXD, SEQ ID No.: 39 and conserved sequences thereof) SEQ ID No.: 13. A vector comprising said isolated nucleic acid and an isolated vancomycin resistant organism comprising such a vector.

5. Claim : 20 and 22 (partial)

a method for reducing vancomycin resistance in a vancomycin-resistant organism comprising enhancing expression of a vanH promoter in the organism, wherein the vanH promoter is not operatively coupled to a vancomycin resistance gene of the organism. Said method wherein the vanH promoter is contained on an enterococcus vector and enhancing expression comprises introducing into the organism

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

an amount of vector to express an amount of the vanH promoter sufficient to bind to phosphorylated VanR and thereby reduce vancomycin resistance in the organism.

6. Claims: 18, 21, 23, 28 (complete) and 20, 22 (partial)

a method for reducing vancomycin resistance in a vancomycin-resistant organism comprising enhancing expression of a vanH promoter in the organism to an amount sufficient to reduce vancomycin resistance in the organism, wherein the vanH promoter is operatively coupled to an antisense vancomycin resistance molecule (or if not operatively coupled then an antisense vancomycin resistance molecule operatively coupled to a vanH promoter is coadministered). Said method wherein the vanH promoter and the antisense vancomycin resistance molecule are contained on an enterococcus vector and enhancing expression comprises introducing into the organism an amount of vector to express an amount of the vanH promoter sufficient to bind to phosphorylated VanR and thereby reduce vancomycin resistance in the organism.

A method for reducing vancomycin resistance in a vancomycin-resistant organism comprising introducing into the organism a vector comprising a VanR-responsive promoter (vanH) operatively coupled to the vanA antisense molecule. A vector comprising a vanH promoter operatively coupled to an isolated nucleic acid molecule that hybridizes under strinhgent conditions to a nucleic acid molecule selected from the group consisting of SEQ ID No.: 1-13. An isolated vancomycin resistant organism comprising such a vector.

# INTERNATIONAL SEARCH REPORT

ormation on patent family members

International Application No
PCT/US 00/22086

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---|---|---|
| WO 9207942 A | 14-05-1992 | FR 2668489 A | 30-04-1992 |
| | | CA 2072350 A | 01-05-1992 |
| | | EP 0507934 A | 14-10-1992 |
| | | JP 5503222 T | 03-06-1993 |
| | | US 5871910 A | 16-02-1999 |
| | | US 6013508 A | 11-01-2000 |
| WO 9000624 A | 25-01-1990 | AT 137806 T | 15-05-1996 |
| | | AU 4180889 A | 05-02-1990 |
| | | DE 68926455 D | 13-06-1996 |
| | | DE 68926455 T | 31-10-1996 |
| | | EP 0424473 A | 02-05-1991 |
| | | JP 3505672 T | 12-12-1991 |
| | | US 5294533 A | 15-03-1994 |
| WO 9812205 A | 26-03-1998 | AU 4485897 A | 14-04-1998 |
| WO 9608582 A | 21-03-1996 | AU 705198 B | 20-05-1999 |
| | | AU 3468195 A | 29-03-1996 |
| | | BR 9508918 A | 21-10-1997 |
| | | CA 2199144 A | 21-03-1996 |
| | | EP 0804616 A | 05-11-1997 |
| | | JP 10504973 T | 19-05-1998 |
| | | NO 971111 A | 09-05-1997 |
| | | NZ 292494 A | 25-03-1998 |
| | | US 6001564 A | 14-12-1999 |
| WO 9414961 A | 07-07-1994 | FR 2699539 A | 24-06-1994 |
| | | FR 2699537 A | 24-06-1994 |
| | | CA 2152066 A | 07-07-1994 |
| | | EP 0672147 A | 20-09-1995 |
| | | JP 8505050 T | 04-06-1996 |
| | | US 6087106 A | 11-07-2000 |
| | | US 5770361 A | 23-06-1998 |
| WO 9901571 A | 14-01-1999 | AU 8327398 A | 25-01-1999 |
| | | EP 0996743 A | 03-05-2000 |